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ABSTRACT

Acute limb compartment syndrome (ACS), a potentially devastating
complication of musculoskeletal trauma, results in muscle necrosis and cell death.
Ischemia and inflammation both contribute to microvascular dysfunction and
parenchymal injury. Currently, surgical fasciotomy remains the only first-line
treatment.
Systemic application of carbon monoxide-releasing molecule-3 (CORM-3)
in animal models of ACS has shown benefits when given in conjunction with
fasciotomy; however, CORM-3 without fasciotomy has never been tested. The
purpose of this thesis was to assess the effects of CORM-3 in ACS without surgical
intervention.
Twenty-nine male adult Wistar rats were used to test the effects of CORM3. Microvascular perfusion, tissue injury, and inflammatory response were
measured at 24, 48, and 72 hours following intracompartmental pressure elevation
and CORM-3 injection.
The results demonstrated partially restored microvascular perfusion,
significantly reduced tissue injury, and significantly

diminished leukocyte

activation (inflammation), indicating the potential of CORM-3 as a pharmacological
agent in the treatment for ACS.

Keywords: acute

compartment

syndrome;
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pressure; carbon monoxide; CORM-3; fasciotomy; microvascular
perfusion, tissue injury; inflammation; non-operative management.
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SUMMARY FOR LAY AUDIENCE

Acute limb compartment syndrome (ACS) is a potentially devastating
complication of limb trauma resulting in muscle and cell death. Lack of blood flow
and white blood cell activation both contribute to vessel dysfunction and tissue
injury. The treatment gold standard is an emergency surgery to relieve the tissue
pressure.
Injection of carbon monoxide-releasing molecule-3 (CORM-3), a substance
that gives off carbon monoxide, in animal models of ACS has shown benefits when
given together with surgery; however, CORM-3 without surgery has never been
tested. Therefore, the purpose of this thesis was to assess the effects of CORM-3
in ACS without surgical intervention.
Twenty-nine male adult Wistar rats were used to test CORM-3. Tissue
perfusion, injury, and white blood cell response were measured at 24, 48, and 72
hours following tissue pressure elevation and CORM-3 injection.
Our results demonstrated that CORM-3 injection without surgery improved
perfusion, reduced tissue injury, and diminished inflammation, indicating its
potential in prolonging the surgical window and its use as a pharmacological
treatment for ACS.
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW

1.1 ACUTE COMPARTMENT SYNDROME
Acute compartment syndrome (ACS) in musculoskeletal trauma is a limbthreatening and, potentially, life-threatening injury. Without prompt surgical
intervention, the elevation of pressure within a closed osseofascial compartment
leads to tissue ischemia, myonecrosis, and nerve injury (McMillan et al. 2019;
Mortensen et al. 2020; Schmidt 2017; von Keudell et al. 2015). The
microvascular compromise that results in a lack of oxygen and nutrient delivery
to the tissues then leads to cellular anoxia and cell death. Ultimately, this can
cause severe functional impairment in extremity function, potential loss of limb,
and even patient death. Although multiple therapeutic agents have been
proposed, the treatment gold standard remains fasciotomy. However, the
surgical window for the procedure is quite narrow before permanent damage
develops (Guo et al. 2019; Mubarak & Hargens 1983). Risk factors for delayed
diagnosis of ACS reported in the literature include poor communication between
physicians, failure of early recognition of signs and symptoms, neurological
injuries, altered levels of consciousness, children, and patient-controlled or
regional anaesthetics (Bhattacharyya & Vrahas 2004; Garner et al. 2014;
Mortensen et al. 2020; von Keudell et al. 2015).
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1.2 ACS: A DIAGNOSTIC CHALLENGE
1.2.1 Aetiologies
There are numerous causes of increased compartmental pressures in the
limbs. They can be divided into traumatic injuries, such as fractures, soft-tissue
trauma without fracture, and penetrating trauma; vascular injuries, such as
arterial/venous

injuries,

intracompartmental

bleeding,

reperfusion

injuries

following ischemia; soft tissue injuries, such as burns, crush injuries, hematomas,
animal bites; iatrogenic causes including, but not limited to, tight casts,
constrictive dressings, prolonged lithotomy position (flexion, elevation, and
abduction of the leg) during orthopaedic surgery, intravenous drug use,
tourniquet application, and anticoagulation (Gourgiotis et al. 2007; Olson &
Glasgow 2005). Reported rare causes of ACS include hypothyroidism, diabetes,
vascular abnormalities, nephrotic syndrome, statins, and ganglion cysts of the
proximal tibiofibular joint (Chautems et al. 1997; Flamini et al. 2008). Although
ACS can occur in the arm, hand, thorax, abdomen, buttock, thigh, foot,
paraspinal muscles, and even in the ocular orbit, it is most commonly seen
following injuries to the lower leg and forearm (Elliott & Johnstone 2003; Garner
et al. 2014; McCallum et al. 2019; Rupprecht et al. 2019).
Bone fractures are the most common cause of ACS when compared to
non-fracture aetiologies, and most commonly occur following tibial shaft fractures
(Elliott & Johnstone 2003; Garner et al. 2014; McQueen et al. 2000; von Keudell
et al. 2015). In a retrospective study, McQueen et al. (2000) found that tibial
diaphyseal fractures were the most common fracture cause of ACS, at 36%,
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followed by distal radius fractures with nearly 10% of cases. Nonetheless, 23.2%
of ACS patients were a result of soft-tissue trauma without fracture. Risk
stratification demonstrated that men under the age of 35 are at greatest risk of
developing ACS following injury (McQueen et al. 2000).

1.2.2 Clinical Findings
Making the diagnosis of ACS is a subject of much debate. It relies on
clinical acumen and monitoring. Intracompartmental pressure (ICP) monitoring is
often used when the diagnosis is equivocal; however, there are no standardized
guidelines for its use (Garner et al. 2014; Mabvuure et al. 2012). Furthermore,
the quality and timing of symptoms can vary between injuries and patients.
Studies have even suggested that muscle damage can occur before the
diagnosis of ACS becomes evident (Frink et al. 2010; Nudel et al. 2016;
Vaillancourt et al. 2004).
Classically, the five Ps (pain, pallor, pulselessness, paralysis, and
paraesthesia) mnemonic has been used as a diagnostic tool for ACS (Donaldson
et al. 2014; Gourgiotis et al. 2007). However, some authors have contended that
they are unreliable. Von Keudell et al. (2015) argue that these represent arterial
ischemia rather than increased compartment pressures. Furthermore, given that
ACS is a dynamic process, the progression of symptoms can be variable (von
Keudell et al. 2015).
Mubarak and colleagues (1978) found that swelling and palpable
tenseness were the first signs of ACS as a result of ICP elevation. Alone,
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however, they are not diagnostic of ACS. They also found that pain with passive
stretch was subjective and unreliable, given that it could be a result of the
traumatic injury rather than ischemia (Mubarak et al. 1978). Furthermore,
Rorabeck and Macnab (1976) found that hypoesthesia and anaesthesia were the
last clinical findings to develop (Rorabeck & Macnab 1976). Meanwhile, Ulmer
(2002) showed that pain, pain with passive stretch, paraesthesia, and paresis are
more useful in ruling out the diagnosis of ACS in the absence of these symptoms
rather than making the diagnosis when they are present. He found that the
individual sensitivities of each symptom ranged from 13% to 19%, whereas their
positive predictive value ranged from 11% to 15%. Meanwhile, both their
specificities and negative predictive values ranged between 97% and 98%.
Nonetheless, in patients at risk of ACS, he demonstrated that the odds of
diagnosing ACS increase with an increasing number of symptoms present; 19%
to 26% with one clinical finding, 68%, 93%, and 98% with two, three, and four
clinical findings respectively (Ulmer 2002).
Heavy reliance on the five Ps can be misleading: pain out of proportion
and pain with passive stretch are important early clinical signs and most reliable
indicators in the diagnosis of ACS (Donaldson et al. 2014; Guo et al. 2019; von
Keudell et al. 2015). However, they can be confounded by the nature of the
injury(ies) suffered, analgesics, altered levels of consciousness, being
uncooperative or unconscious, and pain tolerance (Garner et al. 2014;
Mortensen et al. 2020). Serial and careful examinations thus become crucial.
The other Ps (pallor, pulselessness, paralysis, and paraesthesia) are generally
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considered late signs of persistent ischemia. Paraesthesia and muscle weakness
can be a result of the injury itself rather than ACS. However, if true weakness is
detected, then this could potentially indicate permanent muscle damage (Elliott &
Johnstone 2003). Pulselessness is almost only noted in the very late stages of
ACS. Tense compartments and increasing analgesic requirements are also
important clinical signs that should increase the index of suspicion and must not
be neglected (Garner et al. 2014; Matsen 1975; Mubarak et al. 1978).

1.2.3 Use of Compartment Pressure Monitoring
The concept of compartment pressure monitoring was first introduced by
Whiteside and colleagues in 1975. Proper technique is critical: monitoring should
be done within five centimetres from the zone of injury, and multiple pressure
readings should be done rather than relying on one measurement (Heckman et
al. 1994; Raza & Mahapatra 2015; Whitesides et al. 1975). Compartment
pressure measurement should also be performed in all compartments of the
extremity involved, to avoid missing ACS in adjacent compartments (Erdos et al.
2011; Nudel et al. 2016; Whitesides & Heckman 1996). Needle misplacement,
faulty monitoring systems, and operator experience can all affect pressure
reading (McLaughlin et al. 2014).
Commercial pressure monitoring systems, such as the Stryker IntraCompartmental Pressure Monitor System (Stryker Instruments, Kalamazoo, MI)
or the Synthes Electronic Pressure Transducer (Synthes USA, Paoli, PA) are
readily available on the market. However, when resources are limited, ICP
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monitoring is often performed using simple hospital equipment (Pechar & Lyons
2016; Raza & Mahapatra 2015). These include the simple needle manometry,
wick catheter, slit catheter, central venous manometer, side-ported needle
technique, fibreoptic transducer, and infusion technique (Gourgiotis et al. 2007;
McLaughlin et al. 2014).
The routine use of ICP monitoring and the threshold for fasciotomy remain
controversial. While previous authors have advocated for absolute pressures of
greater than 30mmHg (Mubarak et al. 1978), the more recent literature favours
the Δp value of less than 30mmHg (McQueen et al. 2000). The Δp is a
measurement of the difference between the diastolic blood pressure and the
intramuscular pressure. Thus, a value below 30mmHg suggests inadequate
perfusion. A growing body of literature supports the role of blood pressure in the
role of ICP monitoring, given that tissue perfusion and consequent viability are
dependent on blood pressure (Gourgiotis et al. 2007; Whitesides et al. 1975). In
patients with tibial fractures, McQueen and Court-Brown (1996) demonstrated
that upwards of 43% of patients would have undergone unnecessary
fasciotomies had they used ICP measurement alone (McQueen & Court-Brown
1996).
It has been demonstrated that routine compartment pressure monitoring
can lead to unnecessary fasciotomies in the alert, oriented, and cognitively sound
patient (Guo et al. 2019; Janzing & Broos 2001; Tiwari et al. 2002). In a
prospective study of patients with tibial fractures, Janzing and Boos (2001)
compared patients who had “true” ACS (i.e. those either having undergone
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fasciotomy or having residual physical exam symptoms consistent with
compartment syndrome 12 months after injury) with patients without ACS (i.e.
those who did not undergo fasciotomy and having no residual symptoms 12
months after injury). The data revealed that unnecessary fasciotomies would
have been performed in 6.2%, 3.1%, and 2.1% of patients based on symptoms
alone, absolute ICP >30mmg, and Δp <30mmHg, respectively. Meanwhile, if
decision to fasciotomy were based on ICP monitoring alone, missed ACS would
have been found in 47.4% and 29.0% of patients based on absolute ICP
>30mmg and Δp <30mmHg, respectively. Sensitivity and specificity for
diagnosing ACS was 0.67 and 0.89, respectively, based on symptoms alone;
0.83 and 0.65, respectively, based on ICP >30mmHg; 0.89 and 0.65,
respectively, based on Δp <30 mmHg (Janzing & Broos 2001). In another study
of patients with lower extremity injuries but no fasciotomy, 18 out of 19 patients
had at least one ICP reading >30mmHg, with 12 patients exceeding 45mmHg
and 16 patients with at least one Δp measurement of <30mmHg, without any
clinical evidence of ACS (Prayson et al. 2006). A mathematical and quantitative
analysis of ACS was also performed, arguing that even though monitoring may
be beneficial, it is not yet fully reliable, given the non-uniform pressure
distribution in the compartments and that permanent damage to the soft tissues
can occasionally occur even before the onset of ACS symptoms (Nudel et al.
2016). Therefore, ICP measurement is recommended as an adjunct, rather than
a sole diagnostic tool (Garner et al. 2014).
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Some authors have advocated for continuous ICP monitoring in patients at
risk of ACS, arguing that it may detect it early, before the onset of clinical
symptoms, hence reduce time to fasciotomy. This type of monitoring can be
carried out by connecting the compartment catheter to an arterial line transducer.
However, obtaining precise measurements can be technically challenging and
has a learning curve associated with it (Matsen et al. 1976; McLaughlin et al.
2014; McQueen & Court-Brown 1996; von Keudell et al. 2015). In a review of
patients with a tibial fracture in which their compartment pressures were
continuously monitored coupled with careful clinical examination did not lead to
an increase in the rate of unnecessary fasciotomies (Al-Dadah et al. 2008).
There is no question regarding the benefit of using ICP monitoring in
patients with risk factors that could delay the diagnosis of ACS. These include
young children, intoxicated patients, patients with equivocal symptoms or altered
levels of consciousness, patients with nerve injuries, use of epidural anaesthesia
or nerve block, polytrauma patients, and high-energy injuries (Janzing & Broos
2001; McQueen et al. 2000).

1.2.4 Alternative Diagnostic Tools
Other proposed diagnostic tools for ACS include intramuscular oxygen
partial pressure monitoring (Doro et al. 2014; Weick et al. 2016), near-infrared
spectroscopy (NIRS) (Mancini et al. 1994; Shuler et al. 2011), monitoring
localized perfusion using ultrasound or laser Doppler (Abraham et al. 1998;
Edwards et al. 1999), and intramuscular glucose and pH monitoring (Doro et al.
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2014). In a canine model of ACS, oxygen partial pressure of <30mmHg was
reported to have a 100% sensitivity and a 100% specificity as a diagnostic tool.
In addition, intramuscular glucose concentrations of <97mg/dL had 100%
sensitivity and 75% specificity (Doro et al. 2014). Although the data looks
promising, these are still in the experimental phase in human adults.
NIRS has been proposed and has gained more traction in recent years. Its
proponents explain that blood flow should increase at the site of injury. A
decrease or absence of blood flow could be used as a diagnostic tool for ACS
and could be used as a continuous monitoring device (McMillan et al. 2019;
Shuler et al. 2011). However, a recent study revealed poor reliability in patients
with lower leg injuries, as well as a high number of erroneous NIRS readings
(Schmidt et al. 2018).
Magnetic resonance imaging has limited use in the early acute setting, as
the swelling and edema are not differentiated between early signs of ACS or from
the injury itself. It can, nonetheless, confirm ACS once the diagnosis is
established. However, at that point, a significant delay in the treatment would
occur (Mabvuure et al. 2012).

1.2.5 Missed or Delayed Diagnosis
Patients may also present with variable findings leading to missed or
delayed diagnosis of ACS. Risk factors include patient-controlled or regional
anaesthetics, poor communication between physicians, small children, failure of
early recognition of signs and symptoms, neurological injuries, and altered levels
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of consciousness (Erdos et al. 2011; Garner et al. 2014; Mortensen et al. 2020).
The use of compartment pressure monitoring is highly recommended for patients
with any risk factor for potential ACS; the lack of monitoring in high-risk patients
is a common cause of missed ACS (Al-Dadah et al. 2008; Garner et al. 2014;
McLaughlin et al. 2014).
A case report by Wright et al. (2011) described a 39-year-old male with a
crush injury to the left lower leg, leading to a minimally displaced fracture of the
fibular head. The patient was noted to have absent sensory function over the
dorsal first web space (associated with a foot drop), an absent active extension
of the great toe (extensor hallucis longus), as well as a firm anterior compartment
to palpation. At the same time, very little pain and no significant pain to passive
stretch were noted, with distal pulses palpable and normal. Following fasciotomy,
the patient quickly started regaining his sensory and motor functions. In his case,
the ACS presented in the form of isolated peroneal palsy and an anterior
compartment under great pressure (Wright et al. 2011).
Additional case reports described patients who were given patientcontrolled analgesia (PCA) following tibial intramedullary nail for tibial shaft
fracture (Harrington et al. 2000; O’Sullivan et al. 2002). The PCA masked the
pain, delaying the diagnosis of post-operative ACS. While one patient underwent
fasciotomy of the lower leg with subsequent closure and no long-term sequelae,
another patient ultimately required a below-knee amputation of the leg
(Harrington et al. 2000; O’Sullivan et al. 2002).
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A study conducted by Hope and McQueen (2004) that compared patients
with ACS following fracture and those in the absence of fracture revealed a 13:1
male-to-female ratio in ACS following fracture compared to a 5:1 ratio in ACS
without fracture. The patients without fracture were found to be significantly older
and with more known medical comorbidities. Consequently, the time from
admission to fasciotomy in the non-fracture related patients was delayed, on
average, by more than 12 hours, leading to a significantly greater number of
patients with muscle necrosis, compared to those in the fracture group (Hope &
McQueen 2004).
The diagnosis of ACS in young children can also pose challenges due to
communication difficulties. A case series of patients aged 2 to 18 years revealed
a mean time from admission to fasciotomy greater than 27 hours (Erdos et al.
2011). Thus, careful serial examination and clinical vigilance to any potential
signs of ACS are critical.
Missed or delayed diagnosis of ACS can have serious consequences.
Care must be taken to monitor for signs of shock, renal failure, acidosis,
hypotension, hyperkalaemia, and hypocalcaemia (Guo et al. 2019). Depending
on the amount of muscle(s) involved, missed ACS can lead to ischemic
contractures, secondary deformity, permanent neuromuscular deficits, sensory
deficits, limb dysfunction, infections especially gram-negative sepsis, amputation,
and even death (Donaldson et al. 2014; Elliott & Johnstone 2003; Whitesides &
Heckman 1996).
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Myonecrosis puts patients at high risk of myoglobinuria due to myoglobin
released in the systemic circulation accumulating in the distal convoluted tubules
in the kidneys, leading to acute renal failure requiring aggressive fluid hydration
(Donaldson et al. 2014; Mabvuure et al. 2012; Whitesides & Heckman 1996). In
severe cases of metabolic acidosis, hyperkalaemia, and renal failure,
debridement of necrotic muscles is often indicated to prevent and minimize
systemic failure as well as metabolic complications (von Keudell et al. 2015).

1.2.6 Time to Irreversible Damage
It is generally accepted that irreversible changes begin around 6 to 8
hours following the onset of ACS, although determining the time of onset of ACS
symptoms in itself is often quite challenging (Elliott & Johnstone 2003; Gourgiotis
et al. 2007; Guo et al. 2019; Mabvuure et al. 2012; von Keudell et al. 2015).
However, reports indicate that irreversible damage can also be seen much
earlier, e.g. within 3 hours of ACS onset (Vaillancourt et al. 2004). A study by
Sheridan and Matsen (1976) found that early fasciotomies (within 12 hours of
onset of ACS) resulted in 68% of extremities with normal function and 4.5%
complication rate, while late fasciotomy (mean 37.1 hours from ACS onset)
produced only 8 percent of extremities with normal function and a 54%
complication rate (Sheridan & Matsen 1976). Another study reported on patients
who were operated within three hours of injury already showing evidence of
muscle necrosis and complete muscle necrosis in the affected compartment
within four hours of injury (Vaillancourt et al. 2004). Moreover, in an animal model
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of ACS, Labbe et al. (1987) demonstrated upwards of 90% leg muscle necrosis
within 5 hours of ischemia (Labbe et al. 1987).

1.2.7 Surgeon Variability
It has been demonstrated that there is a degree of variability among
surgeons in the diagnosis and treatment of ACS (O’Toole et al. 2009). A
comparison of seven surgeons within the same institution found a wide variation
of ACS diagnosis, ranging from 2% to 24% of the tibial fractures assessed. The
use of compartment pressure monitors also greatly varied (1.7% to 28.6%), with
similar variation to the percentage of ACS diagnosis (O’Toole et al. 2009).

1.2.8 Medical-Legal Implications
ACS is often subject to litigation. A review found that the factors leading to
unsuccessful

defences

included

poor

documentation,

poor

physician

communication, lack of action once neurovascular signs and symptoms were
identified, increased number of concerning clinical findings, and increased time to
surgery (Bhattacharyya & Vrahas 2004). Furthermore, given the magnitude and
urgency in the treatment of ACS, information disclosed to obtain informed
consent for surgery was often found to be incomplete. Risk of infection, risk of reoperation, the potential need for staged-operations, skin grafts, negative
pressure vacuum dressing, renal failure, and long-term complications were often
omitted when surgeons were rushed to obtain informed consent (Garner et al.
2014).
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1.3 MANAGEMENT OF ACS
ACS constitutes a surgical emergency. When ACS is suspected, all
external compressive forces, such as casts or occlusive dressings, should be
removed immediately. The affected limb should be elevated to the level of the
heart (but not higher) to maximize perfusion (Forsh & Wolinsky 2013; Matsen et
al. 1980). If the signs and symptoms of ACS persist, surgical fasciotomy of all
compartments remains the gold standard. Although numerous nonoperative
treatments of ACS have been studied in various models (tissue ultrafiltration,
hyperbaric oxygen therapy, non-steroidal anti-inflammatory drugs (NSAIDs),
mannitol, antioxidants), there is no conclusive evidence to support their use as a
first-line treatment (Donaldson et al. 2014; Harvey et al. 2012; McLaughlin et al.
2014; McMillan et al. 2019).

1.3.1 Limb Anatomy
1.3.1.1 Leg
The lower leg is the most commonly affected limb in ACS. It includes two
bones (tibia and fibula) and is divided into four compartments: anterior, lateral,
deep posterior, and superficial posterior (Thompson 2016) (Figure 1.1).
The anterior compartment includes the tibialis anterior, extensor hallucis
longus, extensor digitorum longus, and peroneus tertius muscles. These muscles
function primarily in foot and ankle dorsiflexion, are innervated by the deep
peroneal nerve, and the blood supply mainly comes from the anterior tibial artery.
The compartment is delineated by the tibia medially, the interosseous membrane

15

Figure 1.1

Compartments of the leg. Cross-sectional view of the leg
including the tibia and fibula as well as muscles separated into four
osseofascial compartments: anterior, lateral, deep posterior, and
superficial posterior.
Reproduced with permission from Lawendy and Sanders (2010).
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and fibula posteriorly, and the anterior intermuscular septum laterally (Thompson
2016).
The lateral compartment includes the peroneus long and brevis muscles.
They are innervated by the superficial peroneal nerve and are supplied by the
anterior tibial and fibular arteries. The muscles function as the primary foot
evertor while having secondary functions in ankle plantarflexion. The fibula
borders the compartment medially while the anterior and posterior intermuscular
septum borders the front and back, respectively (Thompson 2016).
The muscles in the posterior compartments are mainly responsible for the
plantarflexion of the foot and ankle. While the tibial and fibular arteries, as well as
the tibial nerve, reside in the deep posterior compartment, they are responsible
for vascularizing and innervating both posterior compartments. The deep
posterior compartment includes the flexor hallucis longus, flexor digitorum
longus, tibialis posterior, and popliteus muscles while the superficial posterior
compartment is comprised of the gastrocnemius, soleus, and plantaris muscles.
The compartments are separated by the transverse intermuscular septum
(Thompson 2016).

1.3.1.2 Forearm
The forearm is the second most commonly affected limb in ACS. The
forearm, along with the radius and ulna bones, contains three compartments: the
anterior forearm (divided into superficial, intermediate, and deep layers), the
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posterior forearm, and the mobile wad (brachioradialis, extensor carpi radialis
longus and brevis) (Thompson 2016) (Figure 1.2).
The anterior forearm muscles are primarily responsible for hand and wrist
flexion, as well as forearm pronation. These muscles are either innervated by the
median nerve or by the anterior interosseous nerve, a branch of the median
nerve. They are vascularized by both the ulna and radial arteries (Thompson
2016).
The posterior (or dorsal) forearm muscles are primarily responsible for
hand and wrist extension as well as forearm supination. These muscles are
innervated by the posterior interosseous nerve, a branch of the radial nerve.
They are vascularized by branches of the radial and ulnar arteries (Thompson
2016).
The mobile wad muscles act as secondary elbow flexors proximally. While
the brachioradialis also assists radioulnar joint supination and pronation during
elbow flexion, the extensor carpi radialis longus and brevis allow wrist extension
and hand abduction. The mobile wad is innervated by the radial nerve
(brachioradialis and extensor carpi radialis longus) as well as the posterior
interosseous nerve (extensor carpi radialis brevis). They are vascularized by the
radial artery and brachii profunda (Thompson 2016).

1.3.2 Fasciotomy
The concept of fasciotomy surfaced early in the 1900s. As physicians
attempted to provide treatment for Volkmann’s ischemic contracture, multiple
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Figure 1.2

Compartments of the forearm. Cross-sectional view of the
forearm including the radius and ulna as well as muscles separated
into three different osseofascial compartments: dorsal, volar and
mobile wad.
Reproduced with permission from Lawendy and Sanders (2010).
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reports of myotomies and nerve release were published (Thomas 1909). In 1911,
Bardenheuer described a fasciotomy-type technique, termed aponeurectomy, as
an operative treatment for patients with impending Volkmann’s contracture
(Bardenheuer 1911). The procedure was then advocated by Murphy (1914), who
argued that ischemic paralysis was caused by venous obstruction, hence splitting
the deep fascia would relieve the pressure (Murphy 1914). Jepson (1926) also
reported that decompression helped prevent ischemic contractures (Jepson
1926).
Fasciotomy has since become the forefront of treatment for ACS
(Sheridan & Matsen 1976). By releasing the skin and fascia, the fasciotomy
procedure decompresses the affected compartment(s), allowing the soft tissues
to expand and increase in volume, immediately reducing the compartment
pressures (Schmidt 2017).

1.3.2.1 Threshold for Fasciotomy
Controversy and variability exist when making decisions to intervene.
While some authors advocate for continuous pressure monitoring or routine
compartment pressure checks on all patients at risk, it is generally accepted that,
in the absence of risk factors, the diagnosis of ACS and the decision to intervene
surgically can be made based on clinical symptoms alone. However, if there are
any equivocal symptoms or ambivalence, compartment pressure measurements
should be added as a diagnostic tool (Garner et al. 2014; Mortensen et al. 2020).

20
The thresholds for compartment pressure measurements are also
controversial. The evidence is shifting towards the use of Δp (McQueen & CourtBrown 1996); however, false positive rates may be more significant than
previously believed. A study of patients with tibial shaft fractures but no clinical
evidence of ACS and who did not undergo fasciotomy reported that if the
threshold for surgery of Δp <30mmHg and <20mmHg had been applied, 35%
and 24% of patients, respectively, would have met the criteria for fasciotomy
based on compartment pressures alone (Whitney et al. 2014).

1.3.2.2 Techniques for Fasciotomy
The leg fasciotomy can be done either through a 1-incision technique
laterally or two incisions medially and laterally (Forsh & Wolinsky 2013; von
Keudell et al. 2015) (Appendix I). In the forearm fasciotomy, the volar incision is
performed using either a radial or ulnar curvilinear incision. If needed, a dorsal
incision extending from the lateral epicondyle to the centre of the wrist at the
level of the radioulnar joint is made for the posterior forearm (Forsh & Wolinsky
2013; Gourgiotis et al. 2007) (Appendix I).

1.3.2.3 Delayed Fasciotomy
Some authors argue that fasciotomy should be considered even during
late presentation due to the potential of salvaging any remaining muscle function
(Olson & Glasgow 2005), as well as decreasing the risk of systemic
complications such as rhabdomyolysis and renal failure (von Keudell et al. 2015).
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No guidelines exist, particularly for patients with clearly missed ACS, no viable
muscle function following the onset of symptoms for more than 24 to 48 hours,
and no nerve injury or nerve block to alter the examination. In this scenario,
supportive care has been the main indication, including adequate fluid
resuscitation, analgesics, and splinting, unless there is evolving limb necrosis or
systemic involvement requiring source control (Mabvuure et al. 2012; Schmidt
2017; von Keudell et al. 2015).
Finkelstein et al. (1996) reported that delayed fasciotomy (patients
underwent fasciotomies at an average 56 hours after lower limb ACS was
established) can result in death due to multi-organ failure or amputation due to
infection and sepsis (Finkelstein et al. 1996). Another study reported an infection
rate of 28% in patients undergoing late fasciotomy (>12 hours) (Williams et al.
1997). Complication rates of 4.5% were reported for an early fasciotomy (less
than 12 hours after onset of ACS, with a mean 5.3 hours) and 54% for late
fasciotomy (more than 12 hours after onset of ACS, with a mean 37.1 hours).
Additionally, only 8% of patients in the late group regained normal function
(Sheridan & Matsen 1976).

1.3.2.4 Complications of Fasciotomy
Complication rates of fasciotomy are significant. In a study by Fitzgerald et
al. (2000), long-term complications of fasciotomy included altered sensation
around the wound margins (77%), persistent wound pain (10%), dry scaly skin
(40%), pruritus (33%), discoloured wound (30%), swollen extremity (25%),
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tethered scar (26%), recurrent ulceration (13%), muscle herniation (13%), and
tethered tendon (7%). Furthermore, 12% and 28% of patients stated that they
changed occupation and hobbies, respectively, following fasciotomy (Fitzgerald
et al. 2000). Other complications of fasciotomy include delayed wound closure,
need for surgical reconstruction with grafts or flaps, chronic pain, nerve injury,
infection, permanent muscle weakness, chronic venous insufficiency, renal
failure, and death (Schmidt 2017).

1.3.3 Alternative Treatments
To-date, open fasciotomy remains the gold standard in the treatment of
ACS. Given the morbidity and potential complications, non-surgical management
is rather used as an adjunct to fasciotomies or when fasciotomies are absolutely
contraindicated (Donaldson et al. 2014; McMillan et al. 2019). Several different
techniques have been tested in various models of ACS: tissue ultrafiltration,
hyperbaric oxygen, mannitol, anti-inflammatory medications, and antioxidants.

1.3.3.1 Tissue Ultrafiltration
Odland and colleagues explored the use of tissue ultrafiltration (TUF) as a
potential therapy for ACS. The technique consists of an insertion of small hollow
fibers via catheters into muscle compartments to remove interstitial fluid and thus
decrease compartmental pressures (Harvey et al. 2012). The technique was first
tested in a porcine model of hindlimb ACS by Odland et al. (2005), demonstrating
decreased intramuscular pressure and reduced muscle necrosis in the treated
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limb (Odland et al. 2005). A small, randomized pilot study was then undertaken in
10 patients with tibial fracture. Although no patients suffered from ACS during the
study period, one patient developed ACS in the lateral compartment of the lower
leg and underwent a 4-compartment fasciotomy 22 hours after the TUF catheter
was removed and 46 hours after fracture fixation (Odland & Schmidt 2011).

1.3.3.2 Hyperbaric Oxygen Therapy
Hyperbaric oxygen therapy allows the delivery of 100% oxygen to the
patient (normal atmospheric air contains 21% oxygen). In a case report of a 43year-old male bitten by a Western diamondback rattlesnake who developed ACS
and was recommended fasciotomy by the consulting orthopaedic surgeon, due to
the patient’s refusal of fasciotomy, the therapy consisted of antivenom, mannitol,
and hyperbaric oxygen; the patient fully recovered from the envenomation
without any long-term complications (Gold et al. 2003).
Given the high cost of equipment and paucity of evidence, hyperbaric
oxygen therapy has been largely abandoned as a treatment of ACS (Greensmith
2004), although limited evidence shows that it does offer some value as an
adjunct to standard ACS therapy.

1.3.3.3 Mannitol
Mannitol, a type of sugar alcohol, has previously been suggested to offer
protective effects as an osmotic agent, thereby decreasing muscle edema
(Daniels et al. 1998; Shah et al. 1996). Successful treatment of ACS using
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mannitol was reported in some case reports: a patient presenting with a heat
stroke who later developed ACS of the anterior compartment of the right lower
leg was treated with mannitol alone and developed only mild residual weakness
in the right lower extremity (Daniels et al. 1998); a snakebite that progressed into
ACS was treated with mannitol as an adjunct (along with hyperbaric oxygen and
antivenom) resulting in full recovery and no long-term complications (Gold et al.
2003).

1.3.3.4 Anti-Inflammatories
Significant leukocyte activation (i.e. inflammation) is one of the driving
forces of ACS pathophysiology (Lawendy et al. 2015). As such, the potential of
non-steroidal anti-inflammatory medications as a therapy for ACS has also been
explored in animal models. Cyclooxygenase (COX) enzymes play a key role in
prostaglandin formation, mediating inflammatory processes. While COX-1 is
expressed

constitutively, COX-2

enzymes are

upregulated

during

pro-

inflammatory state (Tsatsanis et al. 2006). In a rat model of ACS, Manjoo et al.
(2010) demonstrated improved muscle perfusion and decreased tissue damage
in animals treated with indomethacin, a COX-2 inhibitor. The observed effects
were a result of indomethacin’s inhibitory effects on activated neutrophils and its
effects as a free radical scavenger. However, it did not affect the apoptotic
activity seen during ICP elevation (Manjoo et al. 2010).
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1.3.3.5 Antioxidants
Antioxidants have potential benefits in situations of oxidative stressinduced microvascular injuries such as trauma, ischemia-reperfusion, sepsis, and
organ failure (Oudemans-van Straaten et al. 2014; Spoelstra-de Man et al.
2018). A previous study of limb ACS demonstrated that exogenous
administration of superoxide dismutase (SOD) antioxidant (an intrinsic enzyme)
and hydroxyl radical inhibitors decreased compartment pressure rise and
improved muscle perfusion (Perler et al. 1990). Meanwhile, the administration of
SOD and mannitol, a hydroxyl radical scavenger, in a canine model of ACS
significantly reduced muscle necrosis compared to control groups but did not
prevent compartment pressure rise (Ricci et al. 1990).
Vitamin C (ascorbic acid) has many antioxidant and immune-supporting
effects such as helping the mediation of direct free radical scavengers, reducing
reactive oxygen species (ROS) production, and increasing the immune response
(Spoelstra-de Man et al. 2018). It has been shown that in a rat model of ACS
within the cremaster muscle, vitamin C pre-treatment in conjunction with
decompression (fasciotomy equivalent) helped maintain muscle function and
decreased extracellular neutrophil infiltration and soft tissue edema (Kearns et al.
2004).
N-acetyl cysteine (NAC), a precursor of glutathione, is a potent antioxidant
by acting as a free radical scavenger (Lejay et al. 2018). Kearns et al. (2010)
demonstrated preserved muscle contractility, decreased oxidant injury, and
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improved muscle viability following decompression and NAC treatment in a
rodent cremasteric striated muscle model of ACS (Kearns et al. 2010).

1.4 PATHOPHYSIOLOGY OF ACS
1.4.1 Historical Perspective
The first description of ACS originates in 1881 by Volkmann. Following his
observation on outcomes of bandages being applied too tightly, he suggested
that ischemic contractures and limb paralysis secondary to ACS following
traumatic injuries were a result of arterial obstruction rather than neurologic
injuries (Volkmann 2007; von Volkmann 1881). Greater attention was brought in
1884 following Leser’s report of seven upper extremity cases treated with plaster
cast and consequent contractures (Leser 1884; Thomas 1909). However, much
debate remained regarding the pathophysiology of ACS. Over the next century,
multiple theories have been postulated, including arterial injuries and arterial
spasms (Griffiths 1940; Plewes 1940), venous obstruction (Bardenheuer 1906;
Brooks 1922; Jepson 1926; Murphy 1914; Plewes 1940), nerve injuries
(Hildebrandt 1906; Thomas 1909), and thromboembolism (Lander 1895; Thomas
1909).
In the 1930s and 1940s, the correlation between increased tissue
pressures and ischemia started surfacing (Hughes 1948; Lewis 1936). Although
fasciotomy or fasciotomy-type procedures had been previously described, the
concept of fascial splitting or decompression became more widely accepted and
emphasized in the treatment of ACS in the 1950s (Benjamin 1957; Mavor 1956;
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Reneman 1975). In 1975, Matsen unified the concepts from the scientific
evidence gathered over the years. He emphasized that the underlying
pathophysiology of ACS was the same, regardless of aetiology, and could occur
within any closed space, regardless of location. Moreover, immediate surgical
decompression of the affected compartments is crucial while suggesting that the
pressure required to cause irreversible damage was not an absolute value but
rather dependent on local factors such as time under elevated ICP, vascular
tone, local blood perfusion, and metabolic rates (Matsen 1975).
While many theories have been postulated, the underlying mechanism
leading to tissue ischemia, myonecrosis, and loss of limb function during
sustained ICP elevation is not yet fully understood. However, it is widely
accepted that increased compartment pressures due to inelastic fascia following
a bony or soft tissue insult leads to progressive microvascular dysfunction and
tissue hypoperfusion. This leads to impaired gas exchange and inability to meet
tissue metabolic demands (Schmidt 2017; von Keudell et al. 2015). Furthermore,
elevated ICP-generated ischemia is associated with leukocyte recruitment, as
well as local and systemic pro-inflammatory cascades, ultimately leading to
cellular anoxia and death, tissue necrosis, and potential loss of limb function
(Donohoe et al. 2018; Lawendy et al. 2015). It is also important to note that
unlike complete ischemia, the deleterious effects of ACS occur despite a patent
macrocirculation where distal pulses are usually palpable unless there is
presence of associated arterial injury. Furthermore, pulselessness is an end-
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result of ACS rather than the cause of tissue necrosis (Gourgiotis et al. 2007;
Hoekman et al. 2005; Leach et al. 1967; Seddon 1966; Whitesides et al. 1975).

1.4.2 Microcirculation in ACS
1.4.2.1 Normal Microcirculation
In normal skeletal muscle, arterioles, capillaries, and venules form the
microcirculatory system (Figure 1.3). Gas exchange and nutrient delivery occur in
the capillaries of terminal vascular beds. In the terminal vascular beds, arterioles
divide into multiple closely spaced capillaries situated along parenchymal cells to
allow oxygen and nutrient exchange. Following material exchange, the blood
flows through the venules and into the systemic venous circulation. In the
microcirculatory system, all vessels are comprised of a single layer of vascular
endothelial cell lining sitting on a layer of extracellular matrix (basement
membrane). The arterioles are surrounded by smooth muscle mesenchymal cells
to allow contractility, while capillaries and post-capillary venules are surrounded
by pericytes rather than smooth muscle cells. The post-capillary venules also
have a rather larger cross-sectional area compared to the corresponding
arterioles resulting in decreased luminal pressures. This allows perfusion through
an arteriovenous pressure gradient (Brown et al. 2006).

1.4.2.2 Microcirculatory Dysfunction
The exact mechanism by which microcirculatory dysfunction and tissue
ischemia occur remains poorly understood. Multiple theories have been
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Figure 1.3

Microcirculation of the skeletal muscle. Normal microcirculation
where an arteriole branches into capillaries. Oxygenated blood
flows from the arterioles (red) into the capillary beds and
deoxygenated blood flows from the capillary beds to collect into the
post-capillary venules (blue).
Reproduced with permission from Bihari (2017).
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postulated in an attempt to explain the phenomenon in relation to increased
compartment

pressures,

including

the

critical

closing

pressure

theory,

microvascular occlusion theory, and arteriovenous (AV) gradient theory. The
critical closing pressure theory suggests that the intravascular arteriolar mural
tension must be sufficiently elevated to overcome extravascular tissue pressure.
Disruption of this equilibrium and an extravascular ICP above the arteriolar mural
pressure in compartment syndrome leads to abrupt arteriole occlusion resulting
in ischemia (Burton 1951; Singh et al. 2004). Additionally, Ashton (1975) also
postulated other mechanisms, including active arteriolar closure mediated by
vasomotor tone due to a decrease in intravascular pressure or extravascular
pressure increase (Ashton 1975). However, the theory has been questioned
when a rabbit model of ACS revealed increased venous pressures and total
intramuscular pressures, while arteriolar dilatation occurred (Reneman et al.
1980). Additionally, in a rodent model, Vollmar et al. (1999) demonstrated no
signs of arteriolar collapse or spasm with elevated intracompartmental pressures
despite blood flow cessation and decreased venular diameter (Vollmar et al.
1999).
In the microvascular occlusion theory, it is assumed that increased ICP
leads to capillary collapse as tissue pressures overcome intracapillary pressures.
Given the low baseline capillary pressures, small extravascular pressure
increments can lead to a reduction in blood flow and subsequent ischemia
(Ashton 1975; Hargens et al. 1978). However, Hartsock et al. (1998)
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demonstrated, in a rat model, that capillaries did not collapse despite an increase
in ICP and even complete cessation of capillary perfusion (Hartsock et al. 1998).
The assumption behind the AV gradient theory is that with rising
intracompartmental pressures, the intraluminal venous pressures also increase,
causing a decrease in the AV gradient and subsequent decrease in perfusion.
This leads to a rise in interstitial pressure due to the extrusion of fluids into the
interstitial space. While the continuous arterial perfusion contributes to increasing
edema and swelling, the increasing extravascular pressures eventually decrease
arterial perfusion, and the cellular metabolic demands are no longer met (Elliott &
Johnstone 2003; Mabvuure et al. 2012; McLaughlin et al. 2014; McMillan et al.
2019). In animal models of ACS, it has been shown that increasing ICP and
extravascular pressure resulted in the reduction of venule diameter, thus
decreasing local perfusion and effectively decreasing the AV gradient, without
complete closure of vessels (Hartsock et al. 1998; Reneman et al. 1980; Slaaf et
al. 1987; Vollmar et al. 1999). The AV gradient theory is the most widely
accepted theory explaining the relationship between the microcirculation and
increased ICP. However, it only accounts for passive microvasculature changes
in response to pressure changes and does not consider local adaptive
responses, endothelial structural changes, and the inflammatory responses
associated with ACS.
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1.4.3 Ischemia and Reperfusion
The exact underlying pathophysiology of ACS still needs to be fully
elucidated. However, the consequences of untreated ACS appear to share
characteristics with ischemia-reperfusion (I-R) injuries. In general, morbidity and
cellular death from ischemic events alone are either a result of prolonged
ischemia (vasculopathy) or lack of oxygen supply due to interrupted blood flow
for periods beyond the organs’ hypoxic threshold (Grace 1994). In ischemic
events, depletion of intracellular adenosine triphosphate (ATP) leads to cellular
membrane damage and loss of transmembrane electrical potential. This leads to
acidosis, osmotic shock, and intracellular calcium overload, with eventual
irreversible mitochondrial damage, protein and enzymatic leakage, and cellular
apoptosis (Grace 1994; Hamburg & Creager 2017; Sharfuddin & Molitoris 2011).
However, histologic findings are often ‘normal’ with preserved tissue architecture
and acellularity, while I-R injuries are characterized by tissue necrosis and
neutrophil infiltration, also observed in ACS (Epstein & McCord 1985; Francis &
Baynosa 2017; Lawendy et al. 2011, 2014). Therefore, understanding the
inflammatory process of I-R injury may help elucidate the mechanisms that lead
to myonecrosis and systemic complications in ACS.

1.4.3.1 Complete Versus Partial Ischemia
ACS is believed to be a type of I-R injury (Francis & Baynosa 2017;
Gourgiotis et al. 2007; Lawendy et al. 2015). However, the degree of ischemia in
ACS remains questioned. Perry and his colleagues have previously compared
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the effects of 3 hours of partial ischemia and complete ischemia, followed by
reperfusion in canine animal models. Although both the complete and partial
ischemia induced cell membrane dysfunction, partial ischemia led to greater
damage than complete ischemia (Perry 1988; Perry et al. 1984; Roberts et al.
1985). Heppenstall and colleagues (1986) demonstrated that increased ICP
resulted in decreased levels of ATP, more severe muscle acidosis and cellular
degeneration compared to tourniquet-induced I-R (Heppenstall et al. 1986).
Conversely, Conrad et al. (2005) found that partial ischemia resulted in
significantly greater early inflammatory cytokine production than incomplete
ischemia. However, after 24 hours of reperfusion, less tissue viability was found
following complete ischemia (Conrad et al. 2005).

1.4.3.2 Low-Flow Ischemia
Recent animal model studies have demonstrated ACS as a “low-flow”
ischemic state (Lawendy et al. 2011, 2015) (Figure 1.4). Normal microvascular
perfusion is predominantly of continuous type (Lawendy et al. 2011; Sadasivan et
al. 1997). However, as the ICP increases, capillaries progress to intermittency
and non-perfusion, although some capillaries remain continuously perfused, thus
decreasing gas exchange and nutrient delivery overall. This partial ischemic state
results in a significant degree of leukocyte activation, cytokine production, and
tissue necrosis (Donohoe et al. 2018; Lawendy et al. 2011, 2015). Therefore,
while the underlying pathophysiology of ACS may not be due to pure I-R
mechanisms, it is thought to be a result of perpetual I-R injuries leading to severe
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Figure 1.4

Microcirculatory dysfunction in compartment syndrome. Hypoperfusion of the capillary beds (low-flow ischemia) causes tissue
injury (brown cells). Subsequently, leukocyte activation occurs in
post-capillary venules and results in inflammation. LKC: leukocytes.
Reproduced with permission from Bihari (2017).
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microvascular dysfunction, tissue ischemia, and eventual macrocirculation
deficits.

1.4.4 Reperfusion Injury
Logically, reperfusion of ischemic tissues serves to restore blood flow,
tissue oxygenation, nutrient delivery, and removal of toxic metabolites.
Paradoxically, it further exacerbates tissue injury and cell death.
The concept of reperfusion injury surfaced in the early 1940s following air
raids during World War II. Patients with crush injuries had localized symptoms
but were systemically well. However, upon restoration of blood flow, they were
found in shock within hours and many passed away within one week (Bywaters &
Beall 1941; Bywaters et al. 1941). Reperfusion following ischemia results in
multiple systemic disturbances, including metabolic acidosis, hyperkalaemia,
myoglobinemia, myoglobinuria, and ultimately renal failure (Erdos et al. 2011).
The systemic return of acidotic blood with venous blood pH usually below 7.2
causes metabolic acidosis, while intracellular potassium (cation) leakage leads to
hyperkalaemia and could be severe enough to cause death. Additionally,
intracellular

enzymes,

dehydrogenase,

and

such

as

creatinine

glutamic-oxaloacetic

phosphokinase,
transaminase,

lactic

can

lead

acid
to

rhabdomyolysis (Grace 1994). Furthermore, ischemic muscles release myoglobin
that can lead to acute renal failure (Matsen 1975; von Keudell et al. 2015).
Re-introduction of oxygen molecules leads to the formation of ROS,
metabolites, endothelial alterations, increased leukocyte activation, neutrophil
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infiltration, inflammatory cascades, and changes in microvascular permeability
(Francis & Baynosa 2017). Several studies have shown that reperfusion of
ischemic tissues with anoxic (without oxygen) blood or limited oxygenated blood
produced considerably less tissue injury (Gute et al. 1998). Consequently,
ischemic tissue injuries appear to be exacerbated by the formation of ROS
(Grace 1994; Gute et al. 1998; Wright et al. 1988).

1.4.4.1 Reactive Oxygen Species and Free Radicals
ROS are oxygen-containing reactive molecules that display much greater
reactivity with other molecules than molecular oxygen (O2) does. Free radicals
are a type of ROS as they contain one or multiple unpaired electrons (Toyokuni
1999). ROS normally play an important role in regulating cell signalling, growth,
and apoptosis. They are also vital in regulating immune, thyroid, and cognitive
functions (Brieger et al. 2012). However, when ROS levels are supraphysiologic
and overwhelm the antioxidant system, they become detrimental, leading to I-R
injuries and various diseases, such as oncologic, cardiovascular, neurologic, and
psychiatric disorders (Brieger et al. 2012; Francis & Baynosa 2017; Lushchak
2015; Toyokuni 1999).
Multiple sources of ROS have been described in biological systems, such
as xanthine oxidase (XO) metabolism, by-products of leukocyte activation,
mitochondrial

electron

transport

chain,

arachidonic

acid

metabolism,

catecholamine autoxidation, endothelial cells, and prostaglandins (Cowled &
Fitridge 2011; Gute et al. 1998). The evidence suggests that XO metabolism and
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leukocyte activation are the main drivers of ROS production in I-R. Superoxide
anion and hydrogen peroxide appear to be the most commonly produced ROS,
while others include, but are not limited to, hydroxyl radical, nitric oxide, and
peroxyl radical (Brieger et al. 2012; Cowled & Fitridge 2011; Grace 1994;
Toyokuni 1999).
XO is a primary producer of ROS in I-R injuries: during the ischemic
phase, glycogen breakdown in the mitochondria leads to increased lactic acid,
resulting in a tissue pH drop, subsequently inhibiting ATP production and
decreasing the transmembrane gradient. ATP is subsequently broken down into
adenosis,

inosine,

hypoxanthine,

and

xanthine.

Concomitantly,

as

the

transmembrane gradient diminishes, intracellular sodium rises while potassium
escapes into the extracellular space, and calcium is released from the
mitochondria into the cytoplasm (Cowled & Fitridge 2011). Calpain, a calciumdependent

cytosolic

protease,

is

then

activated,

converting

xanthine

dehydrogenase (XD) to XO. During reperfusion, molecular oxygen reacts with
XO, catalysing the formation of uric acid and superoxide anion. Superoxide anion
can further be converted to hydrogen peroxide and hydroxyl radicals (Cowled &
Fitridge 2011; Epstein & McCord 1985; Perry & Fantini 1987) (Figure 1.5). In
contrast, in its physiologic role, XD reacts with nicotinamide adenine dinucleotide
(NAD+), converting hypoxanthine to xanthine and NAD+ to nicotinamide adenine
dinucleotide phosphate (NADPH) rather than reacting with molecular oxygen,
and does not produce ROS (Gute et al. 1998).
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Figure 1.5

Generation

of

reactive

oxygen

species

in

ischemia-

reperfusion. During ischemia, ATP is degraded and XD converted
to XO. Upon reperfusion, XO catalyses the conversion of
hypoxathine to superoxide anions; these then initiate the production
of hydrogen peroxide and superoxide radical, leading to lipid
peroxidation and tissue damage.
Reproduced with permission from Cowled and Fitridge (2011).
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The evidence that free radicals play a major role in I-R has been shown in
multiple experiments. Superoxide dismutase (SOD), a free radical scavenger,
has been shown to decrease free radical levels and tissue damage (Gute et al.
1998; Perler et al. 1990; Perry & Fantini 1987; Salvemini & Cuzzocrea 2003).
Other endogenous antioxidants, such as catalase, glutathione peroxidase,
histidine, and vitamin E play a significant role in maintaining equilibrium and
physiologic levels of ROS; however, during I-R, the antioxidant system becomes
overwhelmed and is unable to maintain its scavenging function (Francis &
Baynosa 2017).

1.4.4.2 Lipid Peroxidation
A major consequence of ROS production is structural and functional
damage to the phospholipid-derived cell membrane (Gaschler & Stockwell 2017;
Grace 1994). Following reperfusion, superoxide contributes to free ferrous ion
release, catalysing the formation of hydroxyl radicals and peroxyl radicals from
hydrogen peroxide. These radicals then remove a hydrogen atom in the
methylene group (-CH2-) between two unsaturated bonds (double covalent
bonds) in the lipid molecule, which creates a new carbon-centred radical. When
this new carbon-centred radical reacts with molecular oxygen, a lipid-peroxyl
radical (ROO-) is formed; it then abstracts another hydrogen atom from another
methylene group in the cell membrane, forming lipid peroxide (ROOH). Molecular
oxygen then reacts with the newly created carbon-centred radical, creating a
chain reaction, ultimately leading to cellular permeability and cell death (Cowled
& Fitridge 2011; Gaschler & Stockwell 2017; Grace 1994).
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1.4.4.3 Thromboxane
Plasma thromboxane A2 is derived from arachidonic acid that is released
from lipid peroxidation. Released within minutes of I-R injuries, it promotes
vasoconstriction and platelet aggregation (Mazolewski et al. 1999). A rat model
of I-R with administration of thromboxane A2 receptor antagonist demonstrated a
significant decrease in vasoconstriction (Mazolewski et al. 1999).

1.4.4.4 Leukocyte Activation
The production of ROS has a downstream effect on leukocyte activation
and endothelial injury. Superoxide promotes the production of inflammatory
mediators such as platelet-activating factor and leukotrienes. It also activates
leukocyte chemoattraction and endothelial adhesion proteins, leading to
neutrophil infiltration (Kubes et al. 1990a; Lehr et al. 1991; Lewis et al. 1988;
Rubanyi & Vanhoutte 1986). Leukocyte chemoattraction creates an additive
effect of ROS production through NADPH oxidase (Gute et al. 1998).
Leukocytes contain NADPH oxidase and can oxidize O2 into superoxide;
superoxide is further converted to hydrogen peroxide (Cowled & Fitridge 2011;
Gute et al. 1998). Activated neutrophils undergo degranulation and release
myeloperoxidase (MPO), which then catalyses the formation of hypochlorous
acid (HOCl) from hydrogen peroxide and chloride ions. This ROS activates the
secretion of matrix metalloproteinases (MMPs). MMP secretion is tightly
controlled and plays an essential role in angiogenesis, arteriogenesis, and
extracellular matrix remodelling (Dejonckheere et al. 2011; Hobeika et al. 2008).
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However, during I-R, MMP upregulation leads to further basement membrane
and tissue destruction (Cowled & Fitridge 2011; Dejonckheere et al. 2011; Gute
et al. 1998; Hobeika et al. 2008).
Leukocyte proteinases, such as neutrophil elastase and MMPs, further
amplify leukocyte adherence and endothelial transmigration (Owen 2008; Stowe
et al. 2009). Previous mice studies with either neutrophil elastase or MMP-9
deficiency demonstrated diminished leukocyte adherence, decreased brain
infarct size and blood brain barrier deficiency, and reduced extracellular matrix
destruction in cerebral I-R (Gidday et al. 2005; Stowe et al. 2009). Other animal
studies showed significant decrease in liver injury (Okajima et al. 2004; Soejima
et al. 1999), renal injury (Matsuyama et al. 2008), and pulmonary injury (Ishikawa
et al. 2003) following neutrophil elastase inhibition in the context I-R. MMP
inhibition also showed similar effects in animal studies of cardiac (Cheung et al.
2000; Wang et al. 2002), cerebral (Chen et al. 2018), and renal as well as other
tissue models (Kunugi et al. 2011) of I-R. Neutrophil elastases have been shown
to independently promote neutrophilic and endothelial receptors that allow
leukocyte adherence and transmigration (Woodman et al. 1993; Yamaguchi et al.
1998) while MMPs have degrading effects on the basement membrane,
extracellular matrix, and interstitial tissue (Cheung et al. 2000; Wang et al. 2002,
Kunugi et al. 2011).
Platelet-activating factors also play detrimental roles in causing interstitial
edema and leukocyte adhesion to the endothelium. Free radicals promote the
activation of phospholipase A2, which then leads to the formation of platelet-
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activating factors, a leukocyte chemoattractant. Lewis (1988) demonstrated that
hydrogen peroxide catalysed the synthesis of platelet-activating factors via the
endothelium, inducing leukocyte-endothelial adhesion (Lewis et al. 1988).
Platelet-activating factor antagonists have also been found to play a role in
attenuating leukocyte adhesion and cellular extravasation (Kubes et al. 1990a,b).
Lipid peroxidation of the cell membrane leads to the release of arachidonic
acid. Arachidonic acid then leads to the production of leukotrienes (LTs)
(Gaschler & Stockwell 2017). LTs affect the endothelial cytoskeleton by
increasing

membrane

permeability,

smooth

muscle

contraction,

and

vasoconstriction (Cowled & Fitridge 2011), as well as activation of endothelial
adhesion molecules, such as CD18 (Grace 1994). Furthermore, leukotriene B 4
also mediates neutrophil-generated hydrogen peroxide and elastase (proteolytic)
production (Welbourn et al. 1991).

1.4.4.5 Interaction Between the Endothelium and Leukocytes
During reperfusion, neutrophils are recruited to the ischemic areas, adhere
to the endothelium, and transmigrate into the extravascular space (Ley et al.
2007). This is a multi-step process, initially described by Du Trochet in 1824 (Du
Trochet 1824), known as the leukocyte adhesion cascade (Figure 1.6). While
knowledge surrounding the leukocyte adhesion cascade is still evolving, the
current model of the cascade features nine distinct steps: capture, rolling, slowrolling, arrest, adhesion, intravascular crawling, paracellular transmigration, and
transcellular transmigration (Eltzschig & Collard 2004; Ley et al. 2007).
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Figure 1.6

Leukocyte activation sequence in inflammation. Activated
leukocyte sequence includes leukocyte capture/tethering, rolling,
firm adhesion, arrest and extravasation. It is mediated by various
adhesion

molecules

such

as

selectins,

integrins,

and

Ig

superfamily.
Adapted with permission of Springer Nature from Ley, Laudanna et
al. (2007).
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The process of neutrophil capturing (known as endothelial tethering,
where the neutrophil makes first endothelial contact) and rolling (slow movement
along the endothelial lining) are mediated by selectins and integrins. Initially, Lselectin is expressed on leukocytes; P-selectin and E-selectin are expressed on
the endothelium (Ley et al. 2007). During reperfusion, P-selectin (normally stored
in α-granules of platelets and Wiebel-Palade bodies of the endothelium) is
quickly expressed on to the endothelial cell surface (Cowled & Fitridge 2011;
Lum & Roebuck 2001). Inflammatory mediators promote de novo transcription
and production of E-selectin, taking several hours until full expression (Ley et al.
2007).
Leukocyte rolling is then mediated by integrins, leading to eventual firm
adhesion and arrest. Leukocyte cell surface receptors α 4β7 integrin and very late
antigen-4 (VLA-4) contribute to leukocyte rolling along the endothelium,
interacting

with

mucosal

vascular

addressin

cell-adhesion

molecule-1

(MADCAM-1) and vascular cell-adhesion molecule-1 (VCAM-1), respectively.
(Cowled & Fitridge 2011; Ley et al. 2007).
Leukocyte adhesion is mediated by integrins and immunoglobulin
superfamily (Ig). The CD11/CD18 αβ-integrin complexes mediate adhesion:
CD11a/CD18, also known as lymphocyte function-associated antigen-1 (LFA-1),
is expressed on all leukocytes, while CD11b/CD18, also known as macrophageassociated

receptor-1

(MAC-1),

is

expressed

on

certain

monocytes,

macrophages, lymphocytes, natural killer cells, neutrophils, and granulocytes
(Ley et al. 2007; Lum & Roebuck 2001). CD11a and CD11b are constitutively
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expressed. Both neutrophilic-integrin complexes interact with immunoglobulin
superfamily, including intercellular adhesion molecules 1 and 2 (ICAM-1 and
ICAM-2) on the endothelium, whereas VLA-4 binds with VCAM-1 during the
rolling phase to initiate arrest. ROS, along with pro-inflammatory cytokines,
further promote CD11/CD18 complex and ICAM-1 interaction (Cowled & Fitridge
2011; Eltzschig & Collard 2004; Ley et al. 2007; Lum & Roebuck 2001).
Neutrophil

transmigration

is

triggered

by

a

chemoattractant

transendothelial gradient. Emigrating leukocytes must pass through three distinct
barriers: endothelial cell (rapid penetration, <5 minutes), endothelial cell
basement membrane (penetration time around 5 to 15 minutes), and pericytes.
During I-R, β-integrins promote greater leukocyte-endothelial interactions,
leading to the transmigration of neutrophils. Platelet-associated cell adhesion
molecule-1 (PECAM-1), also a member of the immunoglobulin superfamily, is
constitutively expressed on endothelial cells, leukocytes, and platelets. It is a
major protein facilitating transmigration of leukocytes through both the
paracellular route (at the junctions between endothelial cells) and the
transcellular route (within the body of the endothelium) (Albelda et al. 1991; Ley
et al. 2007; Woodfin et al. 2007). The leukocyte-bound PECAM-1 interacts with
endothelial PECAM-1 promoting transendothelial leukocyte movement, upstream
integrin activation (including MAC-1), and upregulates neutrophil integrin α6β1,
which enables PECAM-1-mediated migration through the perivascular basement
membrane. (Berman & Muller 1995; Privratsky et al. 2010). Studies of proinflammatory conditions have previously revealed diminished severity of disease,
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reduced leukocyte endothelial transmigration, and reduced migration into the
interstitium when PECAM-1 was inhibited (Privratsky et al. 2010; Ley et al. 2007;
Woodfin et al. 2007). Other endothelial mediators of transmigration are junctional
adhesion molecules (JAMs), including JAM-A, JAM-B, JAM-C, as well as ICAM1, ICAM-2, CD99 antigen, and endothelial cell-selective adhesion molecules (Ley
et al. 2007; Lum & Roebuck 2001). Junctional adhesion molecules interact with
leukocyte ligands LFA-1, VL-4, and MAC-1. (Lum & Roebuck 2001; Tuma et al.
2008; Woodfin et al. 2007).

1.4.4.6 Cytokines/Chemokines
Cytokines and chemokines play a significant role in the pro-inflammatory
response of I-R injury. During I-R, calcium phosphate complexes and uric acid
levels

increase

and

bind

onto

inflammasomes,

assisting

with

the

upregulation/production of tumour necrosis factor-α (TNF-α) and interleukin-1β
(IL-1β) by tissue macrophages and neutrophils (Kalogeris et al. 2016; Martinon et
al. 2002). These cytokines enable toll-like receptor stimulation through
intracellular pathways, leading to an upregulation of nuclear factor kappa lightchain of activated B cells (NF-κB) transcription factor activity. As a result,
platelet-activating

factors,

monocyte

chemoattractant

protein-1

(MCP-1),

chemokine ligand 5 (also known as RANTES), and other interleukins (IL-)
including IL-6 and IL-8 are produced and released. Cytokines and chemokines
work synergistically with leukocyte-endothelial adhesion proteins, causing further
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neutrophil chemoattraction, cellular infiltration, and edema (Kalogeris et al. 2016;
Lum & Roebuck 2001; Lutz et al. 2010; Martinon et al. 2002).
Functions of TNF-α include chemoattraction of neutrophils, upregulating
ICAM-1 expression on the vascular endothelium, stimulating production of
downstream cytokines, and apoptosis. It has a high affinity for TNF-α receptor-1
and TNF-α receptor-2 (Cowled & Fitridge 2011). Studies have demonstrated that
inhibition of TNF-α receptor-1 can prevent downstream effects and programmed
cell-death (Jiang et al. 2009). Unlike complete ischemia followed by reperfusion
(Bihari et al. 2017), ICP elevation in a rat model of ACS led to a sustained
increase in serum TNF-α levels, with a second peak (biphasic TNF-α elevation)
occurring after fasciotomy (Lawendy et al. 2016). Meanwhile, IL-1β is released by
mast cells and macrophages to stimulate the production of downstream
cytokines. IL-1β inhibition studies have shown to lessen the pro-inflammatory
response, chemokine expression, and apoptotic events in I-R injuries (Furuichi et
al. 2006; Lutz et al. 2010).
In a rat model of ACS, neutralizing TNF-α alone or both TNF-α and IL-1β
together significantly reduced tissue injury but not with IL-1β neutralization alone.
TNF-α with or without IL-1β neutralization significantly decreased leukocyte
activation and inflammation, while IL-1β neutralization alone had partial
suppressive effects (Donohoe et al. 2018).
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1.4.4.7 Nitric Oxide
Nitric oxide (NO) is synthesized by nitric oxide synthase (NOS) enzyme
existing in three forms: constitutive (cNOS), inducible (iNOS), and endothelial
(eNOS). During the ischemic phase, there is a surge of eNOS within minutes.
However, during reperfusion, eNOS functions decline and NO levels, important in
maintaining vascular tone, decrease. During later stages of reperfusion, cytokinemediated upregulation of iNOS from mast cells, neutrophils, and macrophages
leads to an increase in NO production. However, NO function is bimodal. While
its production from eNOS during ischemia appears to be cytoprotective and acts
as an antioxidant, the late surge from iNOS expression results in further oxidative
stress and interacts with superoxide to form peroxynitrite free radical (Cowled &
Fitridge 2011; Khanna et al. 2005).

1.4.4.8 Complement
I-R has also been shown to lead to an activation of the complement
cascade. Active peptides, such as C3a and C5a, increase microvascular
permeability and exert chemotactic effects on neutrophils. They also increase
CD18 expression and increase neutrophil adhesion to the endothelium (Grace
1994). Heideman et al. (1988) demonstrated increased serum C3a and C5a as
well as elevated serum terminal complement complexes in patients with acute
limb ischemia. Following amputation, these peptide levels returned to normal
range. Multiple complement inhibitors, at various points of the complement
pathway, have been found to decrease tissue injury and organ damage in I-R

49
(Heideman et al. 1988). However, none were able to completely prevent tissue
injury, suggesting that complement activation plays only a partial role in the
underlying pathophysiology of I-R (Arumugam et al. 2006).
Despite their important physiologic functions in maintaining homeostasis,
inflammation and ROS production in the context of ACS and I-R injuries
contribute to extensive tissue damage, organ dysfunction, and systemic
complications.

1.5 HEME METABOLISM AND OXIDATIVE STRESS
Despite the dependence of living organisms on oxygen to survive, the
oxygen required to maintain life is intrinsically toxic due to its capabilities of
inducing oxidative stress. Therefore, compensatory mechanisms have evolved to
allow for survival in such toxic environment. One of the most ubiquitous
mechanisms is heme oxygenase (HO) metabolism (Morse & Choi 2005).
The importance of HO was highlighted by Yachie et al. (1999), who
reported on the first case of HO deficiency: a 2-year-old child presented with
growth retardation, developmental delay, hepatomegaly, asplenia, and persistent
hemolytic anemia requiring regular erythrocyte transfusions. The mother had two
previous intrauterine death that could have been related to HO deficiency; the
child did not survive beyond the age of 6 (Kawashima et al. 2002; Yachie et al.
1999).
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1.5.1 Heme Oxygenase
HO is an enzyme that catalyses heme degradation (Figure 1.7). It was first
described in 1968 by Tenhunen and colleagues (Tenhunen et al. 1968).
Subsequently, three isoforms of HO were isolated: the inducible form, HO-1, and
constitutively expressed HO-2 and HO-3 (Hayashi et al. 2004; Maines et al.
1986; Mccoubrey et al. 1997).
HO breaks down the heme porphyrin ring and cleaves the α-methene
bridge, releasing carbon monoxide, biliverdin, and iron. Oxidation reaction
between HO, NADPH-Cytochrome P450 reductase complex, and oxygen further
converts biliverdin to bilirubin (catalysed by biliverdin reductase) and iron to
ferritin (Ryter & Choi 2016; Wu & Wang 2005).
Bilirubin is increasingly recognized as an antioxidant. For example, it has
been shown that small amounts of bilirubin can protect neural cells from
hydrogen peroxide oxidant in vitro (Baranano et al. 2002). There appears to be a
correlation between low bilirubin levels and increased risk of coronary artery
disease and myocardial infarction (Djoussé et al. 2003; Hopkins et al. 1996;
Schwertner et al. 1994).
The regulatory effects of HO-1 on iron levels have also been shown to
prevent cell death by controlling intracellular iron levels (Ferris et al. 1999; Li &
Stocker 2009). An in vitro study also demonstrated that ferritin itself might have
endothelial antioxidant properties (Balla et al. 1992).
HO-1, normally expressed at low levels, is upregulated in response to
stressors, such as fever, heat, heavy metals, infection, lipopolysaccharides,
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HO

CO
Fe2+

Biliverdin-IXα

BVR

Bilirubin

Figure 1.7

Heme degradation pathway. Heme derived from hemoglobin is
broken down into biliverdin, carbon monoxide (CO), and free iron
(Fe2+) by heme oxygenase (HO). Biliverdin is then rapidly converted
into bilirubin by biliverdin reductase (BVR).
Reproduced with permission from Bihari (2017).
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oxidative agents, stress, radiation, toxins, and ultraviolet light (Choi & Otterbein
2002; Intagliata et al. 2019; Waza et al. 2018). Previously, stress-induced
proteins have been shown to not only protect cells from immediate stress but
also to fortify the organism to withstand future stresses originating from a
different source. In the late 1980s, a 32kD mammalian stress protein, known as
the heat shock protein-32 (HSP32), had been identified (Shibahara et al. 1987); it
was later proven to be HO-1, the inducible form of HO (Keyse & Tyrrell 1989;
Taketani et al. 1989). Benefits of HO-1 include anti-inflammatory properties,
neuroprotection, and protective effects against cardiovascular, diabetic, hepatic,
and renal diseases (Waza et al. 2018; Wu & Wang 2005).
Although HO-2 is constitutively expressed and its gene expression
remains fairly consistent under stress conditions, it also plays important roles in
neuroprotection of the brain and neurologic disease; protection against
cardiovascular, pulmonary, and renal diseases as well as diabetes; protection
against male reproduction disease and pregnancy-related complications;
protection against oxidative stress and deleterious effects of inflammation
(Intagliata et al. 2019; Wu & Wang 2005). Studies of HO-2 knockout mice have
demonstrated elevated levels of inflammatory cytokines, increased oxidative
stress, and decreased healing potential (Bellner et al. 2009; Chen et al. 2018).
The upregulation of HO has been extensively studied. While HO-1 is
ubiquitously produced and found in virtually all tissues affected by stressors such
as oxidative stress and inflammation, HO-2 is predominantly expressed in the
endothelium, testes, and brain (Dunn et al. 2014; Motterlini & Foresti 2017;
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Yachie et al. 1999). Current techniques involve the use of various protoporphyrin
(Maines & Kappas 1977), adenoviral vector transfer of HO gene construct for
short-term effects, and retroviral vectors for long-term upregulation (Abraham et
al. 2007). Despite its potential, there are currently no clinical trials of HO
upregulation gene therapy in humans and is currently not clinically feasible
(Abraham et al. 2007; Kim et al. 2012; Luo et al. 2018; Motterlini & Foresti 2014).
Therefore, the attention shifted towards the by-products of HO activity, notably
carbon monoxide (CO).

1.5.2 Carbon Monoxide
CO is a diatomic molecule occurring naturally as a colourless and
odourless gas (Ryter & Otterbein 2004). Although CO has a negative connotation
due to CO poisoning, carbon monoxide plays a vital role in cell signalling, cellular
communication, vasodilation, as well as peripheral and central nervous system
neurotransmission (Kim et al. 2006). It also possesses anti-inflammatory, antiproliferative, and anti-apoptotic properties (Kim et al. 2006; Ryter & Otterbein
2004; Weaver 2009).
CO binds to hemoglobin to form carboxyhemoglobin (COHb). CO affinity
for hemoglobin is nearly 200 times greater than that of oxygen (Weaver 2009).
Exogenous inhalation of CO not only increases levels of COHb but also shifts the
oxygen dissociation curve to the left, thus decreasing the ability of the remaining
oxyhemoglobin to release its oxygen into the tissues (Ryter & Otterbein 2004).
Normal endogenous COHb levels from heme metabolism range between 1% and
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3% in non-smokers and less than 10% in smokers (Weaver 2009). Symptoms of
CO intoxication include headache, visual disturbances, dizziness, nausea,
fatigue, decreased dexterity, vomiting, seizures, coma, and death if left
untreated. Although the onset of symptoms starts around COHb levels of 15%
and progresses as the CO levels increase, CO intoxication becomes lethal
around COHb levels of 50-60% (Bleecker 2015). Since oxygen and CO are direct
competitors for hemoglobin binding, the mainstay of CO poisoning treatment is
oxygen therapy, which can include both normobaric and hyperbaric oxygenation
(Kim et al. 2006; Ryter & Otterbein 2004; Weaver 2009).
The majority of endogenous CO is produced from heme metabolism. Daily
production, in the absence of external stressors, reaches upwards of 10mL
(Coburn et al. 1964). However, pathological conditions due to pro-inflammatory
processes, external stressors, and environmental triggers that upregulate HO-1
expression lead to an increase in endogenous CO concentration. Multiple animal
studies

have

confirmed

that

upregulating

HO-1

expression

increases

endogenous CO production, while HO inhibition decreases CO synthesis
(Intagliata et al. 2019; Wu & Wang 2005).

1.5.3 Effects of Carbon Monoxide
Multiple animal studies have demonstrated the benefits of exogenous CO
application. CO therapy has shown inhibition of inflammatory mediators,
decreased rates of apoptosis, decreased edema, and improved organ function in
various animal models of I-R, including rodents (Neto et al. 2004), mice (Zhang
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et al. 2003), and pigs (Lavitrano et al. 2004). Clinically, CO therapy has
demonstrated improved graft healing, function, and survival following cardiac,
intestinal, renal, and pulmonary transplantation (Akamatsu et al. 2004; Lavitrano
et al. 2004; Nakao et al. 2003; Neto et al. 2004; Song et al. 2003; Zhang et al.
2003). Exogenous CO application also appears to decrease hyperoxic and
ventilator-induced

pulmonary

injuries,

increases

survival,

and

inhibits

inflammatory cytokines and leukocytes (Dolinay et al. 2004; Otterbein et al.
2003b). CO also decreased apoptosis and structural damage in mice with acute
hepatic injury (Zuckerbraun et al. 2003).

1.5.3.1 Cellular Signalling
CO has a high binding affinity for heme proteins and transition metals,
such as hemoglobin and myoglobin. Therefore, other potential hemoprotein
targets include guanylate cyclase, cytochrome c oxidase, and cytochrome P450
(Ryter & Choi 2016; Ryter & Otterbein 2004).
CO appears to be a modulator of proteins with important implications on
downstream smooth muscle relaxation, vasodilation, ion channel conductance,
glycogenolysis, and cellular apoptosis (Morita et al. 1995; Motterlini & Otterbein
2010; Ryter & Otterbein 2004). CO has been shown to modulate soluble
guanylate cyclase (sGC) to produce cyclic guanosine monophosphate (cGMP).
These have downstream effects on vasodilation and anti-proliferation. However,
it is a weaker agonist of sGC than NO (Ryter & Otterbein 2004). CO is also a
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modulator of calcium- and voltage-gated potassium channels that are involved in
vasoregulation (Peers 2011; Ryter & Choi 2016; Wang 1998).
CO modulates signalling that controls inflammatory and apoptotic
processes. It is an agonist to mitogen-activated protein kinases (MAPK) such as
p38, c-Jun N-terminal kinases (JNK), and extracellular signal-regulated kinases
(ERK), leading to downstream inhibition of pro-apoptotic cytokines such as TNFɑ, although the exact role of JNK and ERK kinases need further elucidation
(Ryter & Choi 2016; Ryter & Otterbein 2004; Zuckerbraun et al. 2007). Animal
and in vitro studies have shown CO as a potential inhibitor of NADPH oxidaseand mitochondria-dependent ROS, as well as a modulator of iNOS (Nakahira et
al. 2006; Ryter et al. 2007; Sarady et al. 2004; Zuckerbraun et al. 2007).

1.5.3.2 Vasodilation
CO plays an important role in vasoregulation. Although NO is a much
more potent sGC modulator (Ryter & Otterbein 2004), its effect on vascular
smooth muscle cells appears to be independent of NO (Morita et al. 1995).
Suematsu and colleagues (1994, 1995) demonstrated increased perfusion and
vasorelaxation when either CO or cGMP was administered, whereas inhibition of
cNOS and iNOS did not affect this response (Suematsu et al. 1994, 1995). CO
may also have a role in promoting cGMP-independent vasodilation, controlling
calcium-activated potassium ion channels, as illustrated by cerebral arteriolar
dilation in response to CO (Jaggar et al. 2002). Wang et al. (1997) demonstrated
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that vasodilation is induced by both cGMP-dependent and calcium-activated
potassium ion channel-dependent effects simultaneously (Wang et al. 1997).

1.5.3.3 Anti-Apoptotic Effects
Apoptosis, also known as programmed cell death, plays a vital role in
maintaining cellular and tissue homeostasis under normal physiological state and
disease conditions. It is characterized by cell shrinkage, pyknosis (chromatin
condensation), karyorrhexis (fragmentation of the nucleus), and plasma
membrane blebbing, which eventually breaks off into apoptotic bodies and are
engulfed by phagocytes (Linkermann et al. 2013; Van Cruchten & Van den
Broeck 2002). Its mechanism can be separated into extrinsic and intrinsic
pathways. Both pathways lead to downstream caspase -3 and -9 release as well
as proteolytic enzymes that induce cell death. In the extrinsic pathway, TNF-α
induces the pro-apoptotic pathway by initiating death-inducing signalling complex
(DISC), including Fas, Fas-associated death domain, and caspase-8, which
ultimately activates caspase-3 activity. The intrinsic pathway, usually upregulated
in response to irreparable intracellular and DNA damage, is activated through
mitochondrial translocation of Bax protein from the Bcl-2 family, which then
releases pro-apoptotic mediators such as cytochrome c and binds onto apoptotic
protease activating factor-1 (APAF-1), thus triggering caspase activity (Bano &
Prehn 2018; Green & Llambi 2015; Kluck et al. 1997; Soares et al. 2002; Wang
et al. 2011; Zou et al. 1997). Various caspase-independent pathways lead to
apoptosis. Increased intracellular calcium triggers calpain enzyme activation,
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which leads to lysosomal-induced cell death. Calpain also functions as a
cleavage system for apoptotic-inducing factors (AIF) causing DNA damage, while
ROS stimulate AIF release through the activation of poly(ADP-ribose)
polymerase-1 (Bano & Prehn 2018; Hongmei 2012; Kang et al. 2004; Kim et al.
2018).
Apoptosis is biologically distinct from cellular necrosis, also termed
necroptosis. While TNF-α is a strong potentiator of both necroptosis and
apoptosis, they have distinct pathways. In necroptosis, TNF-α mediates receptorinteracting protein (RIP) activation forming the RIP-1/RIP-3 complex. Cell death
is then induced by mixed lineage kinase domain-like protein phosphorylation
leading to cell membrane damage (Linkermann & Green 2014; Liu et al. 2019a;
Vanlangenakker et al. 2011a,b).
Many studies have demonstrated that CO displays anti-apoptotic
properties. Brouard et al. (2000) demonstrated the anti-apoptotic effects of CO,
mediated through activation of p38 MAPK, in an in vitro murine model (Brouard
et al. 2000). A murine model of pulmonary I-R injury also showed an inhibitory
effect of CO on mitochondrial cytochrome c release (Zhang et al. 2003).
Additional studies identified synergistic interaction between the HO-1/CO
pathway, NF-κB-dependent anti-apoptotic genes (A1 and c-IAP2), and p38
MAPK activation in preventing TNF-ɑ-mediated apoptosis (Brouard et al. 2002).
It appears that the NF-κB transcription activity may have both pro- and antiapoptotic effects. While CO interacts with NF-κB sub-genes A1 and c-IAP2 to
promote anti-apoptotic activity, the NF-κB gene in itself can act as a pro-
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inflammatory agent through proteasome pathways and upregulation of
inflammatory mediators via its promoter gene (Soares et al. 2002). Important
components of cellular apoptosis involve caspases (family of protease enzymes),
Fas and Bax proteins (Bcl-2 family), that have been shown to be inhibited by CO
(Ryter & Choi 2016; Wang et al. 2011; Zhang et al. 2003).

1.5.3.4 Anti-Proliferative Effects
The anti-proliferative effects of CO were examined by Morita et al. (1995).
They demonstrated that, under hypoxic conditions, HO-1 and subsequent CO
production significantly increased, leading to the upregulation of cGMP in
vascular smooth muscle cells. The addition of CO inhibitors and CO scavengers
completely inhibited this response. The cGMP produced in the vascular smooth
muscles did not involve NO (Morita et al. 1995).
The CO-cGMP pathway has been suggested to prevent vascular smooth
muscle cell proliferation and intimal hyperplasia (Motterlini & Otterbein 2010;
Ryter & Otterbein 2004). Otterbein et al. (2003) demonstrated CO-induced antiproliferative effects in rodent models, dependent on the activation of both cGMP
and p38 MAPK (Otterbein et al. 2003a).

1.5.3.5 Anti-Inflammatory Effects
CO has been shown to exhibit anti-inflammatory effects, both in vitro and
in vivo. In an in vitro model of sepsis, CO inhibited TNF-ɑ release, along with
other inflammatory markers (Otterbein et al. 2000). Application of CO in an
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orthotopic lung transplant prevented severe intra-alveolar haemorrhage and
intravascular coagulation (Song et al. 2003). CO was also found to significantly
improve renal function, decrease pro-inflammatory cytokine expression and renal
tubular injury, as well as inhibit tubular apoptosis in a kidney transplant model
(Abe et al. 2017). Furthermore, CO has been shown to inhibit NADPH oxidaseand mitochondria-dependent ROS, while also downregulating NF-κB activity,
thereby reducing TNF-ɑ-induced leukocyte-endothelial upregulation of E-selectin,
ICAM-1, and VCAM-1 (Chhikara et al. 2009; Ferran et al. 1995; Ryter & Choi
2016; Soares et al. 2002).

1.5.4 Carbon Monoxide-Releasing Molecules
To avoid the toxicity of CO inhalation, the development of carbon
monoxide-releasing molecules (CO-RMs) was undertaken. CO-RMs are
molecules capable of releasing CO on-demand, delivering it to the tissues
without significant changes in COHb levels (Motterlini & Foresti 2014; Ryter &
Choi 2016).
The first CO-RMs were synthesized by Motterlini et al. (2002) (Table 1.1).
CORM-1 ([Mn2(CO)10]), the first CO-RM produced, contains manganese at its
centre and releases CO rapidly (Motterlini et al. 2002). However, it needs photoactivation and, therefore, has limited use in vivo. CORM-2 contains ruthenium
([Ru(CO3Cl2)]) and requires organic solvents to be dissolved via ligand
substitution making its clinical use also limited. CORM-3 ([Ru(CO)3Cl(glycinate)])
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Table 1.1.

Most common carbon monoxide-releasing molecules (CORMs). CORM-1 and CORM-2 release CO rapidly but are not watersoluble. CORM-3 and CORM-A1 are water-soluble.
Adapted from Motterlini (2007).

Name

Chemical Structure

Solubility

CO Release

CORM-1

DMSO

Light-dependent
Fast (t1/2<1min)
1M CO/mole CO-RM

CORM-2

DMSO

Ligand substitution
Fast (t1/2=1min)
0.7M CO/mole CO-RM

CORM-3

Water

Ligand substitution
Fast (t1/2=1min)
1M CO/mole CO-RM

CORM-A1

Water

pH dependent
Slow (t1/2=21min)
1M CO/mole CO-RM

CORM-F3

DMSO

Metal oxidation
Slow (t1/2=55min)
0.25M CO/mole CORM
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is a water-soluble version of CORM-2, also containing ruthenium. CORM-3 is a
rapid equimolar CO releaser (within 10 minutes of being dissolved in water) and,
thus, has a potential for clinical use (Motterlini et al. 2002; Wu & Wang 2005).
At present, ruthenium does not appear to have any physiological function
while being used as experimental anti-cancer drugs. Consequently, metal toxicity
and DNA alteration remain a concern for human studies (Emsley 1989; Bergamo
& Sava 2011). Alternative forms of CO-RMs that are, in theory, more
physiologically friendly have been developed including CORM-A1 and CORM401. CORM-A1 ([Na2H3BCO2]) contains a boron-centric carboxylic group rather
than a transition metal, allowing pH- and temperature-dependent CO release
rather than ligand substitution. CORM-401 ([Mn(CO)4S2CNMe(CH2CO2H)]), in
contrast, contains a manganese centre and releases 3 moles of CO per mole of
CORM-401. Both forms of CO-RM are slower releasers of CO compared to
CORM-3 with a half-life of approximately 21 minutes (Almeida et al. 2016; FayadKobeissi et al. 2016; Inoue et al. 2017; Motterlini et al. 2005).

1.5.4.1 CORM-3
Administration of CORM-3 has been shown to be beneficial in several
animal models, ranging from aortic vasodilation (Foresti et al. 2004), cardiac
inotropy (Musameh et al. 2009), anti-ischemic effects on renal tissue (Sandouka
et al. 2006), acute liver failure (Yan et al. 2016), vasodilation in cirrhotic rats
(Bolognesi et al. 2007), reduced inflammation in haemorrhagic stroke
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(Yabluchanskiy et al. 2012), and inhibition of leukocyte-derived MPO activity in
vascular endothelial injury (Patterson et al. 2014).
Sandouka et al. (2006) demonstrated improved reperfusion and
glomerular filtration rate in I-R models of kidney transplant following treatment
with CORM-3 (Sandouka et al. 2006). In a murine model of acute liver failure,
CORM-3 significantly inhibited pro-inflammatory cytokines such as TNF-ɑ, IL-1β,
IL-6, and increased IL-10 (an anti-inflammatory cytokine), while also inhibiting the
expression of iNOS, Toll-like receptor-4, and NF-κB transcription activities (Yan
et al. 2016). CORM-3 also displayed an anti-inflammatory effect in haemorrhagic
stroke by inhibiting TNF-ɑ (Yabluchanskiy et al. 2012). In vitro experiments on
the heart also demonstrated significant cardioprotection in I-R models when the
heart was re-perfused with CORM-3 (Clark et al. 2003). Additionally, in an in vitro
human vascular endothelial cell (HUVEC) model of inflammation, CORM-3
significantly inhibited leukocyte-derived MPO activity (Patterson et al. 2014).
MPO is a mediator of oxidative stress, important in the innate immune system.
However, when excessive leukocytes are activated during severe inflammatory
responses, stimulation of MPOs and subsequent ROS production contribute to
vascular and organ dysfunction (Cepinskas et al. 2008; Patterson et al. 2014).
Recently, CORM-3 has been found to show promise as a possible
pharmacological agent in the treatment of ACS. In a rat model, the administration
of CORM-3 at fasciotomy led to improved microvascular perfusion, significantly
decreased tissue injury, and diminished tissue leukocyte activation (Lawendy et
al. 2014). In a preclinical porcine model of ACS, CORM-3 not only improved
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muscle injury but also significantly inhibited inflammation at both local and
systemic levels. This was characterized by complete inhibition of systemic TNF-α
release as well as suppression in oxidative bursts of leukocytes (Bihari et al.
2018).
To transition the promising results into human studies, Bihari et al. (2019)
developed an in vitro model of ACS, using HUVEC stimulated with serum
isolated from ACS patients. Incubation of HUVEC with ACS serum led to an
endothelial barrier breakdown, an increase in oxidative stress and apoptosis, as
well as polymorphonuclear leukocyte activation. The application of CORM-3
offered significant protection against these detrimental effects (Bihari et al. 2019).

1.6 PURPOSE OF THE THESIS
If not treated promptly, ACS is a limb-threatening and often life-threatening
condition. The current gold standard for treatment is surgical fasciotomy. While
the pathophysiology of ACS is not entirely understood, it shares many similarities
with I-R injury. Although it is generally accepted that irreversible tissue damage
occurs around 6 to 8 hours, previous studies have demonstrated myonecrosis as
early as 3 hours within the onset of ACS.
The effects of complete ischemia (where the onset is known, as all
circulation is cleanly cut off) and subsequent reperfusion injury have been
extensively studied. Unlike complete ischemia, however, ACS occurs in the face
of patent vessels; distal pulses are present in the majority of ACS patients,
indicating that the macrocirculation within the involved compartments is still
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intact, while the microcirculation becomes dysfunctional. The diagnostic
challenges become even greater, as ACS is a clinical diagnosis, and multiple risk
factors can delay timely diagnosis. The onset of ACS in itself is often difficult to
identify.
Despite proposed non-operative alternatives in case reports or small case
series, none have been proven to be an effective first-line treatment or a
substitute for fasciotomy. Recently, the role of CO as a potential pharmacological
therapeutic agent for the treatment of ACS has been explored. In preclinical
studies, using both small (rat) and large (porcine) models of ACS, administration
of CO, in the form of water-soluble CO donor, CORM-3, at fasciotomy has
resulted in decreased microvascular perfusion deficits, diminished tissue injuries,
blocked leukocyte activation, and inhibition of systemic TNF-α release (Bihari et
al. 2018; Lawendy et al. 2014).
The purpose of this thesis was to evaluate the effects of CO in ACS
without fasciotomy, by investigating its short- and longer-term effects on
microvascular dysfunction, myonecrosis, and inflammatory response. For this
experiment, CORM-3 was chosen as the CO donor, given its water solubility and
rapid CO release. We hypothesized that the administration of CORM-3 would
produce a lasting beneficial effect. The ultimate goal is to identify whether CO
can be used as a stand-alone first-line treatment of ACS, or at least extend the
surgical window. For the purpose of this thesis, the terms ‘elevated ICP’ and
‘ACS’ were used interchangeably. However, it is important to note that ACS is a
clinical diagnosis and is only applicable to humans.
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CHAPTER 2: MATERIALS AND METHODS

2.1 ANIMAL CARE
The experimental protocol for the study was approved by the Animal Care
Committee of the Canadian Council on Animal Care (CCAC) at the University of
Western Ontario, London, Ontario, Canada. The daily animal care, handling, and
housing conformed with the guidelines established by the CCAC. The rats were
housed in pairs, in clear plastic cages, and under 12:12 light:dark cycle. They
had access to food and water ad libitum.

2.2 ANIMAL DESCRIPTION
Twenty-nine male Wistar rats were used for this study. Their body weight
ranged between 190g and 260g.

2.3 CARBON MONOXIDE
A water-soluble CO donor, carbon monoxide-releasing molecule-3
(CORM-3)

(tricarbonylchloro-glycinate-ruthenium(II),

[Ru(CO)3Cl-glycinate];

molecular weight 295gmol-1), was used in this experiment. It was synthesized in
our lab using previously published method (Clark et al. 2003). A stock solution of
10mg/ml was prepared fresh, in isotonic saline, just before the injection. Each rat
received 10mg/kg of CORM-3 intravenously, via the left lateral tail vein.
Inactive CORM-3 (iCORM-3) was used as an inert control. iCORM-3 was
prepared by dissolving CORM-3 in normal saline 72 hours prior to injection; this
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allowed it to release all CO from the stock solution prior to administration to the
animals. The lack of CO in iCORM-3 had been previously confirmed
spectrophotometrically by myoglobin conversion assay (Bihari et al. 2017).

2.4 EXPERIMENTAL SETUP
2.4.1 General Overview
ACS was generated in the right hind limb of rats by elevating ICP under
general anaesthesia. Elevated ICP was maintained at Δp <30mmHg (ICP value
of 40-65mmHg) for 2 hours. Experimental drug injections were administered;
animals were then allowed to recover. Adequate pain control was provided to all
rats using buprenorphine (Buprenex 0.05mg/kg IM q8h). During the recovery
period, the rats were housed individually to prevent identification errors and
erratic social behaviour.
Following the proper recovery time in accordance with the assigned
experimental group (24, 48 or 72 hours), all rats were re-anaesthetised and
intravital video microscopy (IVVM) was performed. At the conclusion of IVVM,
animals were euthanized by cardiac puncture under the deepest plane of
anaesthesia.
Sham animals underwent all procedures, but the ICP remained at baseline
level of 0mmHg.
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2.4.2 Anaesthesia
Anaesthesia was carried out using inhalational isoflurane. Induction of
general anaesthesia was achieved using 5% isoflurane in 100% oxygen gas at a
flow rate of 2L/min. Anaesthesia was maintained using 2% isoflurane at a flow
rate of 0.5L/min and adjusted as needed to maintain adequate anaesthetic depth.
A digital rectal thermometer probe was used to monitor core body temperature. A
heating lamp was used to maintain body temperature at 37°C.

2.4.3 Acute Compartment Syndrome
The experimental model was previously described by Lawendy et al.
(2011). Briefly, ICP elevation was achieved by continuous infusion of isotonic
saline solution into the anterior compartment of the hindlimb using a 24-gauge
angiocatheter (BD, Franklin Lakes, NJ). An electronic compartmental pressure
monitoring system (Synthes USA, Paoli PA) was inserted into the posterior
compartment through a 14-gauge angiocatheter (BD, Franklin Lakes, NJ). Both
the anterior and posterior compartments became isobaric as the pressures rose,
which allowed ICP monitoring from the posterior compartment. Continuous saline
infusion was administered through a gravity-feed system where the isotonic
saline bag was placed 120cm above the infusion site (Figure 2.1).
Elevated ICP was maintained between 40mmHg and 65 mmHg to achieve
Δp between diastolic blood pressure and ICP of <30mmHg for two hours. It has
been previously estimated that one hour of ischemia in rodents is equivalent
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Figure 2.1

Schematic illustration of rat ACS experimental setup. Isotonic
saline is continuously infused in the anterior compartment of the
hind limb, maintaining elevated ICP between 40mmHg and
65mmHg.

An

angiocatheter

connected

to

an

electronic

compartmental pressure monitoring system is inserted in the
posterior compartment.
Reproduced with permission from Bihari (2017).
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to about four hours in humans, given the metabolic differences (Hoppeler &
Weibel 2005; Hulbert et al. 2007; Lawendy et al. 2011; Marquet et al. 2005);
hence two hours of elevated ICP should be the equivalent of about eight hours in
humans.

2.5 EXPERIMENTAL GROUPS
Rats were randomly assigned to one of four main groups: (1) sham, (2)
ACS followed by 24 hour recovery, (3) ACS followed by 48 hour recovery, and
(4) ACS followed by 72 hour recovery. Each group was further subdivided into
animals that received CORM-3 or those receiving iCORM-3 injection. In this
experiment, each rat received only a single dose of either CORM-3 or iCORM-3.

2.5.1 Sham
Six animals underwent all procedures, but the compartment pressure
remained at baseline level of 0mmHg. Rats received an injection of CORM-3
(n=3) or iCORM-3 (n=3), followed by IVVM.

2.5.2 ACS with 24hr Recovery
Eight rats underwent ACS, followed by IV administration of CORM-3 (N=4)
or iCORM-3 (N=4). They were then allowed to recover for 24 hours, as described
in section 2.4.1. Following the recovery period, animals were re-anaesthetised
and underwent IVVM.
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2.5.3 ACS with 48hr Recovery
Seven animals underwent ACS, followed by CORM-3 (N=4) or iCORM-3
(N=3) injection. They were then allowed to recover for 48 hours. Following
recovery period, all animals were re-anaesthetised and underwent IVVM.

2.5.4 ACS with 72hr Recovery
Eight rats underwent ACS, followed by CORM-3 (N=4) or iCORM-3 (N=4)
injection. They were then allowed to recover for 72 hours. Following recovery
period, all animals were re-anaesthetised and underwent IVVM.

2.6 INTRAVITAL VIDEO MICROSCOPY
2.6.1 Muscle Preparation
Under general anaesthesia, the extensor digitorum longus (EDL) muscle
was prepared for IVVM using careful dissection and handling to avoid iatrogenic
injuries. A lateral incision over the experimental hind limb was made. The
underlying biceps femoris was exposed and incision through its fascial layer was
undertaken, allowing retraction of the muscle. The tibialis anterior (TA), peroneus
longus (PL), and lateral gastrocnemius (LG) muscles were then identified.
Meticulous dissection was carried out to avoid traumatizing the saphenous vein
and to maintain adequate hemostasis. Subsequently, the EDL was identified
between TA and PL. The underside of TA and PL were gently brushed off and
retracted without touching the fibers of EDL. Once exposed, the distal EDL
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tendon identified over the ankle was ligated using 3-0 silk and severed as close
as possible to the bony insertion site.
Following EDL preparation, the rat was then carefully moved onto the
stage of IVVM microscope; the EDL muscle belly was partially reflected anteriorly
into the saline bath containing vital dyes and stabilized using the 3-0 silk ligature
(Potter et al. 1993).

2.6.2 Vital Dye Staining
Two

fluorescent

dyes,

ethidium

bromide

(EB)

(Sigma

Aldrich,

Mississauga, ON) and bisbenzimide (BB) (Sigma Aldrich, Mississauga, ON) in
concentrations of 5μg/ml each were added to the saline bath in which the EDL
was placed on the microscope slide. Both dyes bind DNA, hence label cell nuclei.
Due to its size and hydrophilic nature, EB does not penetrate intact cell
membrane; therefore, it was used to label injured or dead cells (i.e. cells with
compromised cellular membrane). BB, a lipophilic dye, is able to enter all cells,
thus labelling the nuclei of all cells (Daly et al. 1992; Potter et al. 1995). Cellular
injury was expressed as the ratio of EB-labelled nuclei to BB-labelled nuclei
(EB/BB).

2.6.3 Microscopy
Microscopy was used to assess microvascular perfusion, tissue injury, and
leukocyte behaviour. Microvascular perfusion was assessed by recording five
transilluminated adjacent fields of view containing complete capillary beds using
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20x objective (final magnification 700x) for 60 seconds each. An additional 10
seconds was recorded from the same fields of view under epifluorescence
illumination using the proper filters for BB (excitation wavelength = 343nm,
emission wavelength = 483 nm) and EB (excitation wavelength = 482 nm,
emission wavelength = 610nm) in order to assess tissue injury.
Leukocyte behaviour was assessed by transillumination in five randomly
chosen post-capillary venules, with diameter of at least 20μm using 40x objective
(final magnification 1400x) for 45 seconds each.
All videos were saved into the computer using Adobe Premiere software
for offline video analysis.

2.7 OFFLINE VIDEO ANALYSIS
2.7.1 Microvascular Perfusion
Three equidistant parallel lines were drawn perpendicular to the capillary
axis on the video monitor. Microvascular perfusion was quantified by counting
the number of continuously-perfused capillaries (CPC), intermittently-perfused
capillaries (IPC), and non-perfused capillaries (NPC) crossing each line, based
on red blood cell movement (Lawendy et al. 2014). The CPC, IPC, and NPC
were expressed as a percentage of the total number of capillaries.

2.7.2 Tissue Injury Analysis
The ratio of EB-labelled cells to BB-labelled cells (EB/BB) was used to
evaluate the extent of tissue injury (Potter et al. 1995).
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2.7.3 Analysis of Leukocytes
Leukocyte behaviour was analyzed by counting the number of rolling and
adherent leukocytes per 30 seconds in each venule. An adherent leukocyte was
defined as a cell remaining stationary for at least 30 seconds, while a leukocyte
was considered rolling if it remained in close contact with the vessel wall during
its entire movement (Granger et al. 1989). The ImageJ software (NIH, Bethesda,
MD) was used to measure the venular area. The results were expressed as the
number of leukocytes per 30 seconds per 1000μm2 (Lawendy et al. 2011).

2.8 STATISTICAL ANALYSIS
All data were expressed as a mean ± standard error of the mean (SEM)
and analysed using two-way analysis of variance (ANOVA) with Tukey multiple
comparison post-hoc test. Data analysis was performed using Prism version 7.0c
for Mac OS X (GraphPad Software Inc., San Diego, CA). The statistical
significance was set at p<0.05. Minimum sample size calculation, based on
leukocyte adhesion, was performed using StatMate (GraphPad Software Inc.,
San Diego, CA) with power set at 85%. We estimated that 48 rats were required
to show a significant difference at an 85% confidence level. However, due to the
COVID19 pandemic and circumstances out of our control, we were unable to
perform analysis on the desired number of rats.
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CHAPTER 3: RESULTS

3.1 MICROVASCULAR PERFUSION
3.1.1 Continuously-Perfused Capillaries
ICP elevation led to a significant decrease in CPC, from 79±9% in the
sham group, to 39±5%, 44±10%, 35±4% in the 24-, 48-, and 72-hour post-ACS
groups, respectively (two-way ANOVA, p<0.0001). Administration of CO donor,
CORM-3, resulted in significant increase in the number of CPC to 57±3%,
61±3%, 53±7% at 24, 48, and 72 hours post-ACS, respectively versus 81±4% in
sham (p=0.0042) (Figure 3.1). CORM-3 had no effect on the number of CPC in
sham animals.

3.1.2 Intermittently-Perfused Capillaries
In response to ACS, the number of IPC increased, from 10±6% in the
sham group, to 27±10%, 26±5%, 30±5% at 24, 48, and 72 hours post-ICP
elevation, respectively (two-way ANOVA, p=0.0365). Application of CORM-3
resulted in 28±4%, 18±4%, 22±6% IPC at 24, 48, and 72 hours post-ACS,
respectively versus 9±3% in sham (p=0.3474, n.s.) (Figure 3.1). CORM-3
injection had no effect on the number of IPC in sham rats.
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Figure 3.1

The effect of CORM-3 on skeletal muscle perfusion following
ACS. ACS resulted in a significant microvascular dysfunction;
administration of CO donor, CORM-3, partially restored the
perfusion.

CPC:

continuously

perfused

capillaries;

IPC:

intermittently perfused capillaries; NPC: non-perfused capillaries
(*p<0.001 from sham; †p<0.05 from ACS).
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3.1.3 Non-Perfused Capillaries
A significant increase in the number of NPC was observed, from 11±3% in
the sham group, to 35±5%, 29±7%, 35±4% at 24, 48, and 72 hours post-ICP
elevation, respectively (two-way ANOVA, p=0.0006). Administration of CORM-3
led to a significant decrease in the number of NPC in all time-matched groups
(16±2%, 20±1%, 25±3% at 24, 48, and 72 hours, respectively versus 11±3% in
sham, p=0.0012) (Figure 3.1). CORM-3 did not produce any effect on the number
of NPC in sham rats.

3.2 TISSUE INJURY
Significant tissue injury in ACS rats was observed: the EB/BB ratio of
0.03±0.003 in the sham group rose to 0.31±0.08, 0.41±0.08, 0.40±0.1 at 24, 48,
and 72 hours post-ICP elevation, respectively (two-way ANOVA, p=0.0004).
Administration of iCORM-3 had no effect on tissue injury in any of the ACS
animals, while CORM-3 significantly reduced the EB/BB ratio to 0.15±0.05,
0.17±0.05, 0.20±0.04 at 24, 48, and 72 hours post-ICP elevation, respectively
(two-way ANOVA, p=0.0013). Additionally, no significant difference was found
between the sham group and animals that received CORM-3 (Figure 3.2).
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Figure 3.2

The effect of CORM-3 on skeletal muscle tissue injury
following ACS. ACS resulted in a significant increase in tissue
injury; administration of CO donor, CORM-3, significantly reduced
tissue injury caused by ICP elevation (*p<0.05 from sham; †p<0.05
from ACS).
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3.3 LEUKOCYTE BEHAVIOUR
3.3.1 Leukocyte Rolling
Significant increase in leukocyte rolling following ICP elevation was
observed at 24 hours: from 4±2 leukocytes/30sec/1000μm2 in the sham group, to
19±5 leukocytes/30sec/1000μm2 in the ACS group (p=0.0007). At 48 and 72
hours post-ACS, leukocyte rolling was 9±1 and 10±2 leukocytes/30sec/1000μm2,
respectively; values which were not significantly different from the sham group
(p=0.3603 and p=0.2749, respectively). Administration of CORM-3 resulted in a
significant

reduction

in

rolling

leukocytes

at

24

hours:

5±1

leukocytes/30sec/1000μm2 versus 2±0 leukocytes/30sec/1000μm2 in sham
(p=0.0013). In the 48- and 72-hour groups, leukocyte rolling was 10±3 and 10±3
leukocytes/30sec/1000μm2, respectively, which were not significantly different
from iCORM-3 groups (p=0.9998 and p=0.9999, respectively) (Figure 3.3).

3.3.2 Leukocyte Adhesion
ICP elevation led to a significant increase in adherent leukocytes, from
1±1 in the sham to 5.6±0.8, 8.2±2.4, 6.7±1.0 leukocytes/30sec/1000μm2 at 24,
48, and 72 hours following ACS, respectively (two-way ANOVA, p=0.0059).
Administration of CORM-3 significantly reduced leukocyte adhesion to 2±1, 1±0,
3±1 leukocytes/30sec/1000μm2 at 24, 48, and 72 hours post-ICP elevation,
respectively (two-way ANOVA, p=0.0001) (Figure 3.4).
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Figure 3.3

The effect of CORM-3 on leukocyte activation following ACS:
leukocyte rolling. ACS led to a significant increase in leukocyte
rolling; administration of CO donor, CORM-3, attenuated this
response at 24hr post-ACS (*p<0.05 from sham; †p<0.05 from
ACS).
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Figure 3.4

The effect of CORM-3 on leukocyte activation following ACS:
leukocyte adhesion. ACS led to a significant increase in leukocyte
adhesion; administration of CO donor, CORM-3 attenuated this
response at all time points (*p<0.05 from sham; †p<0.05 from
ACS).
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CHAPTER 4: DISCUSSION

4.1 OVERVIEW OF RESULTS
ACS is a surgical emergency for which the gold standard treatment is
open fasciotomy. However, ACS remains a clinical diagnosis with multiple risk
factors that can lead to delayed or missed diagnosis. Consequently, delayed
management of ACS can result in loss of limb function, systemic complications,
and even death (Mortensen et al. 2020; Olson & Glasgow 2005; Pearse et al.
2002; Via et al. 2015).
Given the challenges of timely diagnosis and surgical intervention, many
alternatives have been previously proposed. Yet, none have been proven as a
stand-alone first line treatment. Furthermore, fasciotomies have their own set of
issues and may also result in significant debilitating complications (Fitzgerald et
al. 2000; McMillan et al. 2019; Schmidt 2017). Therefore, there is a need to
develop alternative therapeutic interventions in the treatment of ACS, or at least,
to prolong the surgical window.
Over the last decade, CO has shown therapeutic potential in animal
models of ACS when administered upon fasciotomy. However, its effects in ACS
without fasciotomy are unknown. Therefore, the aim of this experimental project
was to assess the use of CO, liberated from water-soluble CORM-3, in
ACS without surgical intervention.
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4.1.1 The Effect of ACS
Although the true underlying pathophysiology of ACS remains elusive,
there is mounting evidence that ischemic insult may be occurring concurrently
with reperfusion injury, rather than a pure ischemic event followed by reperfusion
syndrome. Reperfusion following ischemia causes oxidative stress and mediates
oxygen-derived ROS, leading to cellular damage through lipid peroxidation,
leukocyte-endothelial activation, upregulation of inflammatory mediators such as
TNF-α and IL-1β working synergistically along with leukotrienes, thromboxane
A2, prostaglandins, and platelet-activating factors, thus causing further
microvascular dysfunction, changes in vascular permeability, cell death, tissue
necrosis, soft tissue swelling, increased ICP, and potential systemic inflammatory
responses (Cowled & Fitridge 2011; Gourgiotis et al. 2007; Grace 1994;
Lawendy et al. 2014; Lutz et al. 2010; Soares et al. 2002; von Keudell et al.
2015).

4.1.1.1 Microvascular Changes
Hindlimb ICP elevation resulted in a significant increase in non-perfused
and intermittently-perfused capillaries, whereas the number of continuouslyperfused capillaries significantly decreased, leading to a low-flow ischemic state.
These findings are consistent with previous studies of ACS assessing CPC, IPC,
and NPC changes using IVVM in rat models, where microcirculatory deficits were
found to occur by shifting continuous perfusion towards altered and/or absent
flow (Bihari et al. 2017; Lawendy et al. 2011, 2014, 2015; Manjoo et al. 2010). A
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previous canine study had also characterized ACS as an incomplete and
maldistributed microvascular blood flow rather than complete ischemia
(Sadasivan et al. 1997).
The results corroborate with previous studies of I-R, showing early
significant microcirculatory changes. Menger et al. (1992) used a hamster
striated muscle I-R model, showing significant capillary hemodynamic changes at
30 minutes and 2 hours following reperfusion, but very little changes between 2
hours and 24 hours (Menger et al. 1992). In rat gracilis muscle I-R, Olivas et al.
(2001) had demonstrated progressive microvascular dysfunction mainly within
the first 7 hours of reperfusion. However, the magnitude of hypoperfusion saw
very little change between 7 and 48 hours after reperfusion (Olivas et al. 2001).
This suggests rapid and non-reversed microvascular dysfunction when left
untreated, which was reflected in our study. However, given that ischemia occurs
concurrently with reperfusion in ACS, the magnitude of perfusion deficits and
timing of its deleterious effects likely differ from a pure I-R injury.
The no-reflow phenomenon has been used to describe the failure of
capillary reperfusion and has been described in previous cardiac (Schofer et al.
1985), renal (Summers & Jamison 1971), epigastric free flap (May et al. 1978),
and skeletal muscle (Blaisdell 2002) models of I-R. However, its underlying
mechanism remains controversial. Debate still exist whether it is a consequence
of ischemic muscle and cell death leading to non-perfused vessels, or whether
the reperfusion injury ultimately shunts vascular perfusion. The aetiologies of the
no-reflow phenomenon have been separated into two categories: structural and
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functional. Structural no-reflow implies vasoconstriction, microembolization,
endothelial damage, and extravascular compression (interstitial edema) while the
functional variant is a result of leukocyte, erythrocyte, and platelet aggregation,
observed especially in the post-capillary venules (Blaisdell 2002; Durante &
Camici 2015; Maksimenko & Turashev 2012; Niccoli et al. 2010).
The no-reflow phenomenon can be appreciated in our study with the
significant amount of NPC. In ACS, increased fluid extravasation from the
vascular bed increases interstitial pressures leading to ICP elevation; this causes
adjacent capillary lumen compression, progressive non-perfusion and ischemia
(Gute et al. 1998; Lawendy et al. 2011). However, microcirculatory deficits are
not only dependent on passive vasoconstriction secondary to increased
interstitial pressure, but also on pro-inflammatory responses from reperfusion
leading to vascular endothelial damage and tissue necrosis.

4.1.1.2 Tissue Injury
In low-flow ischemia, since there is still a degree of perfusion, reperfusion
injury occurs concomitantly with ischemia rather than a no-flow ischemic event
followed by reperfusion. Thus, parenchymal damage is likely caused by the
perfusion deficits leading to hypoxemia, coupled with the ensuing inflammatory
response (Bihari et al. 2017; Forbes et al. 1996; Gute et al. 1998; Lawendy et al.
2011, 2014, 2015). Although controversial, it appears that reperfusion following
partial ischemia or elevated ICP produces more severe tissue damage than after
complete ischemia (Heppenstall et al. 1986; Perry et al. 1984; Roberts et al.
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1985). However, in a murine I-R experiment, Conrad (2005) demonstrated
significantly reduced tissue viability at 24 hours post-reperfusion following
complete ischemia, despite having greater early inflammatory response from
partial ischemia (Conrad et al. 2005).
In our study, the EB/BB ratio significantly increased, indicating extensive
tissue damage from elevated ICP at all examined time points. The EB/BB ratio
appears to have plateaued at the 48-hour mark, showing slightly higher value
than what was found in the 24-hour group, but minimal difference compared to
the 72-hour time point. Comparatively, an I-R rat study performed by Olivas et al.
(2001) demonstrated muscle necrosis worsening over the first 8 hours, followed
by minimal changes to the damaged tissues between 8 and 48 hours of
reperfusion (Olivas et al. 2001).
Reperfusion injury is a major contributor to the pro-inflammatory response.
In a study by Bihari et al. (2017), no-flow ischemia followed by reperfusion
demonstrated significant increase in EB/BB staining during the 90-minute
reperfusion interval. However, after 2 hours of ischemia and prior to reperfusion,
it was still at nearly the same level as in the sham group, indicating that the
maximum amount of tissue necrosis occurred during reperfusion, and not during
ischemia alone. The results also correlated with the systemic TNF-α levels,
where TNF-α sharply increased at the time of reperfusion (Bihari et al. 2017).
Thus, the pro-inflammatory response and subsequent tissue damage re-enforces
the idea of underlying reperfusion injury in ACS with concurrent progressive
ischemia.
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The assumption that ischemic insult and reperfusion injury are occurring
simultaneously in ACS is based on previous studies demonstrating perpetual and
recurrent local I-R events, free radical generation, and endothelial damages,
especially in peripheral vascular diseases (PVD). Both ambulation and exercise,
but not while at rest, can induce progressive reperfusion syndrome from chronic
hypoperfusion in patients with PVD. Its clinical symptom is known as intermittent
claudication and can eventually progress to critical limb ischemia (Ciuffetti et al.
1991; Dopheide et al. 2013; Hickman et al. 1994). Similar mechanisms have
been observed in the progression of non-healing chronic wounds (Mustoe et al.
2006) and diabetic foot ulcers (Alavi et al. 2014).
In our study, ICP elevation caused significant cellular injury and tissue
damage. Historically, cellular necrosis was thought to be a form of unregulated
cell death, as a consequence of disease process. However, there is increasing
evidence that cellular necrosis is, in fact, mediated by defined (but not fully
understood) molecular pathways, and

is termed

necroptosis. Although

necroptosis shares upstream inflammatory mediators with apoptosis (eg. TNF-α),
their downstream pathways are biologically distinct (Linkermann & Green 2014;
Van Cruchten & Van den Broeck 2002; Vanlangenakker et al. 2011a,b). In I-R
injuries, it appears that both necroptosis and apoptosis are involved in cell death.
A combination of both apoptotic and necrotic cells has been found in I-R studies
of rat gracilis muscles (Wang et al. 2008), murine gastrocnemius muscles (Tran
et al. 2012), as well as other organs, including the brain (Degterev et al. 2005),
heart (Oerlemans et al. 2012), kidney (Linkermann et al. 2013), and lungs
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(Fischer et al. 2000). Previous studies of ACS have shown significant systemic
pro-inflammatory cytokine TNF-α elevation (Bihari et al. 2018; Lawendy et al.
2014, 2016). Although it is impossible to differentiate cell death by necroptosis
and apoptosis in this study, both pathways were likely involved, given that they
are both potentiated by TNF-α.
Leukocytes are a major contributor to tissue damage and muscle necrosis.
Tissue damage appears to be mediated by inflammatory cytokines, such as TNFα and/or IL-1β (Donohoe et al. 2018; Lawendy et al. 2011). Sadasivan et al.
(1997) had previously demonstrated significant reduction in microvascular injury
and neutrophil infiltration in ACS under neutropenic conditions (Sadasivan et al.
1997). In a rat model of ACS, Lawendy et al. (2015) compared ACS in
leukopenic and normal rats. Leukopenia led to the suppression of leukocyte
recruitment and no significant muscle tissue injury was observed. Meanwhile,
leukopenia had no effect on perfusion deficits (Lawendy et al. 2015). This
demonstrated that in ACS, ischemic insult also occurs distinctively from
inflammatory-mediated damage. In our study, elevated ICP also led to leukocyte
activation and was associated with significant tissue injury.

4.1.1.3 Leukocyte Activation
Leukocyte activation in response to elevated ICP showed significantly
higher number of rolling leukocytes at 24 hours, but not at 48 or 72 hours. In fact,
the number of rolling leukocytes trended towards normal in the latter 2 groups
(still elevated compared to sham, but not significantly). Meanwhile, significant
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increase in leukocyte adhesion in post-capillary venules was observed at all time
points, with peak levels occurring at 48 hours post-ICP elevation.
The results corroborate with those of previous experiments examining the
relationship between leukocytes and vascular endothelial inflammation. In a rat
model of endotoxin-induced uveitis (EIU), Miyamoto et al. (1996) demonstrated
peak numbers of rolling leukocytes between 12 and 24 hours (Miyamoto et al.
1996). Another experiment had shown peak rolling leukocyte at 24 hours and
returned to normal by 72 hours (Baatz et al. 1995). In a rat endotoxin-induced
intestinal inflammation study, the peak number of rolling leukocytes was found
between 6 and 12 hours, and subsequently trended towards control-group levels
from 24 to 72 hours while the number of adherent leukocytes peaked at 24 hours
before trending back down (Watanabe et al. 2018). A report of rat hindlimb
allograft rejection found a significant increase in rolling leukocytes up to 24 hours
post-transplantation. The number of rolling leukocytes continued to increase by
72 hours, however, not significantly. Meanwhile, leukocyte adhesion continued to
increase significantly between 24 and 72 hours (Ozer et al. 1999).
The early peak in rolling leukocytes, combined with later increase in
leukocyte adhesion can be explained by the leukocyte-endothelial activation
sequence. The selectin receptors found on leukocytes (L-selectin), endothelium
(E-selectin) and both the endothelium and platelets (P-selectin) act as mediators
of leukocyte rolling behaviour. In I-R injury, inflammatory cytokines, complement
factors, and ROS activate selectins to initiate rolling leukocytes. P-selectins
found in pre-formed pools in Weibel-Palade bodies in the endothelium are quickly
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released

within

30

minutes.

Meanwhile,

E-selectin

is

induced

under

transcriptional control, and will take several hours to reach its peak. Additionally,
shedding of the constitutively expressed L-selectin is inversely proportional to
leukocyte activation and works synergistically with P-selectins to stimulate rolling
leukocytes. Loss of L-selectins is also associated with activation of MAC-1,
important for later ICAM expression (Cowled & Fitridge 2011; Kurose et al. 1994;
Ley et al. 2007; Panes & Granger 1998; Weibel & Palade 1964).
E-selectin appears to return to baseline levels by 24 hours from onset of
inflammatory stimulus, while P-selectin has been found to be upregulated for up
to 24 hours and expressed for up to 48-72 hours following leukocyte cascade
activation (Cowled & Fitridge 2011; Hallahan et al. 1996; Panes & Granger
1998). In rat models, P-selectin was found to be maximally expressed up to 24
hours following cerebral artery reperfusion (Suzuki et al. 1997) and P-selectin
mRNA expression was upregulated up to 24 hours in retinal I-R (Nishijima et al.
2004). In a pig model of inflammation, peak expression of E-selectin was found
within the first few hours while returning to near baseline levels at 24 hours
(Binns et al. 1996). Additionally, all 3 selectins interact with leukocytes via Pselectin glycoprotein ligand-1 (PSGL-1). While P- and L-selectins seem to share
similar binding configuration to PSGL-1, it differs with E-selectin (Somers 2000,
Ley 2003). PSGL-1 binding with E-selectin appears to be transient compared to
P-selectins (Ley & Kansas 2004; Vestweber & Blanks 1999).
To initiate arrest and adhesion, CD11/CD18 neutrophilic αβ-integrin
complexes bind onto the endothelial ICAM-1 and ICAM-2 ligands, whereas
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neutrophilic VLA-4 interacts with MADCAM-1 and VCAM-1 ligands. While VCAM1 and ICAM-1 peak expressions have been highly variable, ranging from 6 hours
to 36 hours, these ligands are, nonetheless, highly expressed up to 48 hours
post-activation (Cowled & Fitridge 2011; Eppihimer & Granger 1997; Hallahan et
al. 1996; Langer & Chavakis 2009; Panes & Granger 1998). Therefore, the
higher expression of selectins within the first 24 hours and early weaning help
explain the initial surge in rolling leukocytes while adhesion endothelial factors
usually have increased upregulation up to 48 hours post-activation, if not longer.
Inflammatory cytokines and chemokines play a key role in leukocyte
activation. In a rat model of ACS, Donohoe et al. (2018) identified 16 detectable
systemic cytokines/chemokines, 6 of which were significantly upregulated
following ICP elevation. These included pro-inflammatory cytokines TNF-α, IL-1β,
along

with

chemokines

growth-related

oncogene-α

(GROα),

monocyte

chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein-1α
(MIP-1α). They also found increased levels of anti-inflammatory cytokine IL-10.
Subsequently, administrating TNF-α neutralizing antibodies (NA) alone or TNF-α
NA concurrently with IL-1β NA resulted in a significant decrease of leukocyte
rolling, whereas giving IL-1β NA alone had no effects. Meanwhile TNF-α NA
alone or combined with IL-1β NA produced significant reduction in leukocyte
adhesion, while IL-1β NA alone only produced partial improvements (Donohoe et
al. 2018). Although GROα, MCP-1, and MIP-1α were not tested against NA, they
remain important mediators of pro-inflammatory response and leukocyte
activities, whereas IL-10 is an anti-inflammatory cytokine (Bechara et al. 2007;
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Deshmane et al. 2009; García-Bonilla et al. 2011; Maurer & von Stebut 2004;
Menten et al. 2002; Ouyang & O’Garra 2019). Thus, identifying the exact roles
and temporal activation of these cytokines/chemokines on rolling leukocytes
would help elucidate the differences seen between the earlier and later time
points in our study.

4.1.2 Therapeutic Effects of CORM-3-Derived CO
CO has been found to exhibit potent anti-inflammatory, anti-proliferative,
anti-apoptotic, and vasodilatory effects. However, given the toxicity of inhaled
CO, CO-RMs were synthesized in order to control CO delivery without elevating
COHb levels (Guo et al. 2004; Lawendy et al. 2014; Motterlini & Otterbein 2010;
Ryter & Choi 2016).

4.1.2.1 Effects of CORM-3 on Microvascular Perfusion
Systemic application of CORM-3 led to partial restoration of perfusion
following ICP elevation: there was a significant increase in CPC and decrease in
NPC. Microvascular perfusion remained relatively constant and unchanged
between the 24-, 48-, and 72-hour groups. Although significant microvascular
improvements were observed following treatment with CORM-3, the perfusion
deficit still remained significant compared to the sham group. The results of this
study are comparable with those of ACS treated with CORM-3 at fasciotomy:
CORM-3 significantly restored the number of CPC and reduced the number of
NPC in rat (Lawendy et al. 2014) and porcine models of ACS (Bihari et al. 2018),
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as well as in pure I-R injury (Bihari et al. 2017). However, these studies carried
out microvascular analysis between 45 minutes and 3 hours following elevation
of ICP, whereas we assessed longer-term results.
CO has been shown to mediate vasodilation via sGC. In the endothelial
cGMP-dependent pathway, CO is in fact a weaker agonist than NO (Kajimura et
al. 2010). However, CO appears to mediate NO-independent cGMP in the
vascular smooth muscle cells, preventing proliferation and intimal hyperplasia.
CO also mediates cGMP-independent pathways by mediating calciumpotentiated potassium membrane channels to induce vasodilation (Jaggar et al.
2002; Motterlini & Otterbein 2010; Ryter & Choi 2016; Ryter & Otterbein 2004;
Suematsu et al. 1995; Wang et al. 1997).
NO also plays an important role in vasoregulation. Vasoconstriction is not
only a result of passive changes from increased interstitial pressure and edema,
but also due to a vasomotor component and autonomic dysfunction (Durante &
Camici 2015; Nanobashvili et al. 2003). Pericytes in the microvascular wall act as
contractile cells, activated by vasoactive hormones. Capillary dilatation from
pericyte activity appears to be mediated by the NO/cGMP pathway (Bettaga et al.
2015; Hall et al. 2014; Kelley et al. 1988; Nanobashvili et al. 2003; Sakagami et
al. 2001). CORM-3 has been shown to stimulate NOS in the endothelium and
activate cGMP pathway, while inhibiting NOS in the acetylcholine-induced
endothelium-dependent relaxation (Alshehri et al. 2013). In our study, CORM-3
resulted in improved microvascular perfusion, decreasing the no-reflow
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phenomenon, which could be explained, at least in part, by interplay of
vasodilatory effects of CO and NO.

4.1.2.2 Effects of CORM-3 on Tissue Injury
In our experiments, tissue injury was significantly reduced following
administration of CORM-3. EB/BB ratio in our study ranged between 0.14-0.2,
values that are slightly higher than those found previously, where CORM-3 was
given at fasciotomy or upon reperfusion (Bihari et al. 2017; Lawendy et al. 2014).
However, those results reflect tissue injury at very early time points (45 to 90
minutes) compared to 24, 48, and 72 hours in our current study.
Our results are consistent with those of others who had previously
demonstrated that CORM-3 was capable of lessening cellular damage and
increasing tissue survival, including decreased cardiac infarct size and muscle
damage (Clark et al. 2003; Guo et al. 2004; Varadi et al. 2007), improved renal
graft survival and mitigating parenchymal damage (Sandouka et al. 2006; Vera et
al. 2005), and demonstrated antiapoptotic effects in lung I-R injuries (Zhang et al.
2003). While the exact mechanisms of cellular protection are most likely related
to the vasodilatory and anti-inflammatory properties, there is another possibility:
inhibition of apoptosis. CO appears to target multiple layers of the pro-apoptotic
pathways, including inhibition of cytochrome C oxidase and NADPH oxidasederived ROS (Boczkowski et al. 2006; Taillé et al. 2005; Zuckerbraun et al.
2007), upregulation of NF-kB-dependent anti-apoptotic genes (A1 and c-IAP2)
via P38 MAPK activation and downregulation of ERK1/2 (Boczkowski et al. 2006;
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Brouard et al. 2002; Ryter et al. 2007; Soares et al. 2002; Zhang et al. 2003;
Zuckerbraun et al. 2007).
Leukocytes, particularly neutrophils, also appear to play a significant role
in generating the observed endothelial damage. Activated neutrophils secrete
MPO, leading to the formation of ROS and destruction of cellular membrane
(Dejonckheere et al. 2011; Eltzschig & Eckle 2011; Hobeika et al. 2008; Lutz et
al. 2010; Panes & Granger 1998). Application of CORM-3 was found to modulate
polymorphonuclear (PMN)-induced ROS production, as well as mitigate cell
surface levels of elastase in several in vitro models, with subsequent reduction in
PMN rolling and adhesion along endothelial cells, thus decreasing endothelial
dysfunction (Bihari et al. 2019; Mizuguchi et al. 2009; Patterson et al. 2014). It
can be surmised that, although CO is not a free radical scavenger, it may have
the ability to suppress the oxidative stress indirectly, by modulating the activity of
redox enzymes, thereby minimizing the extent of endothelial injury.

4.1.2.3 Effects of CO and CORM-3 on Leukocyte Activity
In our study, leukocyte-endothelial activation appeared to be inhibited by
CORM-3, as demonstrated by a significant reduction of adherent leukocytes at
24-, 48-, and 72-hour time points. Surprisingly, rolling leukocytes were markedly
reduced by CORM-3 only at 24 hour, but not at later times.
Multiple studies have demonstrated anti-inflammatory properties of CO
and its inhibitory effects on leukocyte activity. For example, animals with acute
pancreatitis or sepsis treated with CO donor, CORM-2, demonstrated significant
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reduction of ICAM-1 and VCAM-1 adhesion molecules, inhibition of inflammatory
cytokines TNF-α, IL-1β, and IL-6, as well as downregulation of NF-kB expression
(Liu et al. 2019a,b). In intestinal and hepatic I-R models, CORM-2 diminished
expression of TNF-α, NF-kB activity, leukocyte and endothelial adhesion
molecules, as well as neutrophil infiltration (Katada et al. 2010; Wei et al. 2010).
CO was found to inhibit a variety of inflammatory cytokines, including MCP-1, in
a murine renal I-R (Ruan et al. 2014), while increasing anti-inflammatory cytokine
IL-10 in a rat model of pancreatitis (Chen et al. 2010) and a murine model of
acute liver failure (Yan et al. 2016). Various in vitro and in vivo experiments have
shown that application of CORM-3 led to inhibition of TNF-α-mediated activation,
translating into a decrease in VCAM-1, E-selectin, integrin complexes, as well as
caspases (pro-apoptotic) activity (Bergstraesser et al. 2012; Bihari et al. 2019;
Motterlini 2007; Song et al. 2009; Vadori et al. 2009). Additionally, CORM-3 has
been shown to have cytoprotective effects in cardiac and renal I-R through
upregulation of mitochondrial ATP-dependent potassium channels and calciumpotentiated potassium channels, downregulation of NADPH oxidase-generating
superoxide free radical, suppression of NF-kB activity, and inhibition of E-selectin
and ICAM-1 (Caumartin et al. 2011; Clark et al. 2003; Guo et al. 2004).
CO appears to suppress Toll-like receptor activity and NF-kB gene
transduction pathways involved in inflammatory response. By inhibiting NF-kB
activity, TNF-α-mediated upregulation of adhesion molecules (such as E-selectin,
ICAM-1 and VCAM-1) is suppressed (Chhikara et al. 2009; Choi et al. 2017;
Soares et al. 2002). CO has also shown potent inhibitory effects on
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lipopolysaccharide-induced upregulation of TNF-α and IL-1β (Otterbein et al.
2000). Previous studies have demonstrated, in vitro, suppression of leukocyteendothelial interaction of platelet-activating factor, CD11b integrin surface levels,
cell surface elastase (proteolytic enzyme), MMP activity and neutrophil-derived
MPO activity; substantially decreasing adhesion and transmigration of leukocytes
in inflammation-stimulated environments (Bihari et al. 2019; Inoue et al. 2017;
Megías et al. 2007; Mizuguchi et al. 2009; Patterson et al. 2014; Urquhart et al.
2007; Zhuang et al. 2017).
While CORM-3 appears to have a significant effect on leukocyte adhesion
and transmigration, its effects on leukocyte rolling remains questioned. In our
experiment, significant increase in rolling leukocytes occurred only at 24 hours,
but not at 48 or 72 hours post-ICP elevation. This can be explained, at least in
part, by selectin modulation and their differential PSGL-1 binding (Ley 2003;
Somers et al. 2000; Vestweber & Blanks 1999). Previous studies of CO-RMs
have shown suppression of the E-selectin receptors in renal rat I-R (Caumartin et
al. 2011) and in vitro HUVEC models (Song et al. 2009). However, CORM-3’s
effect on P-selectin remains largely unknown. A study of lipopolysaccharidestimulated platelet model using blood from healthy volunteers demonstrated a
decrease in platelet P-selectin expression following CORM-2 treatment (Liu et al.
2016). Given that CORM-3 attenuation of rolling leukocyte behaviour only
occurred at 24 hours, its suppression is likely through the inhibitory effects of CO
on inflammatory cytokines. However, CORM-3’s significant therapeutic effect on
adherent leukocytes in all 3 groups suggests that CO also has a direct cytokine-
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independent effect on adhesion molecules, such as immunoglobulin superfamily
(eg. ICAM-1, VCAM-1) and αβ-integrin complexes (eg. LFA-1, MAC-1) (Bihari et
al. 2017; Lawendy et al. 2014). Finally, uncovering temporal activation and
effects of other inflammatory cytokines/chemokines on leukocytes, as well as
their response to CORM-3 will help further elucidate the leukocyte activity
observed in this study.

4.2 STUDY LIMITATIONS
Despite the encouraging results, there are several limitations to our study.
First, the duration of elevated ICP was based on previous studies, as well as on
physiological and mathematical assumptions (Hoppeler & Weibel 2005; Lawendy
et al. 2011, 2014; Radermacher & Haouzi 2013). Therefore, it was assumed that
2 hours of elevated ICP in rats corresponded to 8 hours in humans. However,
future studies are required to correlate ACS equivalence in rats and humans.
Second, only one injection of CORM-3 was administered, using a single
route. Therefore, whether there is an additive or dynamic effect of multiple
injections and/or injection sites, as well as the optimal rate of CO release in the
treatment of ACS remain unclear.
In this experiment, no functional testing (i.e. assessing rat hindlimb
function) was performed. Thus, no clinical correlations could be made. Finally,
while CORM-3 does not seem to elevate COHb levels in animal models, it has
yet to be tested in humans. How CORM-3 injections translate in humans during
ACS is unknown.
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4.3 FUTURE DIRECTIONS
This study remains an early experimental study of CORM-3 without
fasciotomy. Further studies are required to elucidate its role as a potential firstline treatment in ACS or as an adjunct to prolong the surgical window.
1) Analyze the effects of CORM-3 during shorter intervals, e.g. at 6- and 12hours post-elevation of ICP, to identify whether there are more prominent
effects in the earlier stages.
2) Compare outcomes using different injection doses and frequencies, as well
as alternative routes of administration of CORM-3.
3) Perform functional limb assessments to determine the clinical outcomes of
CORM-3.
4) Further studies are needed to clarify CORM-3’s mechanism of action and its
effects on tissue regeneration.
5) In previous animal studies of ACS, despite undergoing fasciotomies,
inflammatory markers remained elevated systemically, often observed as a
second hit phenomenon. Clinically, acute renal failure, rhabdomyolysis,
systemic shock, and multiorgan dysfunction syndrome can occur despite
fasciotomies. Although CORM-3 has shown its ability to suppress TNF-α and
other inflammatory cytokines, it would be important to determine whether
inhibition of systemic inflammatory cytokines can be sustained long-term
when treated without fasciotomy (Bihari et al. 2017; Donaldson et al. 2014;
Lawendy et al. 2014, 2016; Mabvuure et al. 2012).
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4.4 CONCLUSIONS
Multiple alternative therapies to surgical fasciotomy have been proposed
in the treatment of ACS. However, none of them have been validated as a
potential first-line treatment. While the exact underlying mechanism of CORM-3
still needs further elucidation, it is likely that the CO released has multiple
therapeutic molecular and cellular targets during ACS (Ryter & Otterbein 2004).
In this study, CORM-3 without fasciotomy has demonstrated improved
microvascular perfusion, diminished tissue injury, and mitigated leukocyte
activation. Based on the current literature, it is plausible to assume that CORM-3
played a major role in mediating vasodilation, reducing pro-inflammatory
cytokines/chemokines and formation of ROS, thereby inhibiting leukocyteendothelial adhesion molecules. This study is a novel experiment demonstrating
sustained therapeutic effects of CORM-3 without fasciotomy in the treatment of
ACS, indicating its potential role as a pharmacological agent in the management
of ACS.
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APPENDIX I: FASCIOTOMY TECHNIQUES

Currently, the only gold standard in the treatment of ACS remains surgical
fasciotomy. The goal is to provide immediate pressure relief and decreased
compartmental pressures. By incising the skin and rigid fascia, this increases the
volume of the muscle compartments, thereby reducing the pressure and
restoring microvascular perfusion (Schmidt 2017). During fasciotomy, the
muscles are assessed for colour, consistency, contractility, and perfusion. Any
necrotic tissue should be debrided (Lawendy & Sanders 2010; von Keudell et al.
2015).
The lower leg and forearm are the most commonly affected locations in
ACS (Elliott & Johnstone 2003). In the lower leg, the most frequently described
techniques are the single-incision (lateral incision) technique or two-incision
technique (lateral and medial incisions). A single incision with concomitant
fibulectomy has been previously described (Kelly & Whitesides 1967). However,
this technique has fallen out of favour given that both the two-incision and single
incision without fibulectomy techniques provide adequate release without the
morbidity of fibular removal, while this technique also places the peroneal
vessels and superficial peroneal nerve at risk (Ebraheim et al. 2016; Lawendy &
Sanders 2010). In the forearm, the volar and dorsal approaches are used to
decompress the muscle compartments.
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I.1 LOWER LEG FASCIOTOMY
Although better visualisation of the soft tissues and neurovascular
structures favours the two-incision technique, both approaches have yielded
satisfactory results and demonstrated adequate 4-compartment release (Forsh &
Wolinsky 2013; von Keudell et al. 2015).

I.1.1 Single-Incision Fasciotomy
The patient is positioned supine on the operative table. A tourniquet is
applied to the thigh but not insufflated, and the limb is freely prepped and draped.
A bump is also placed under the hip. A single lateral incision along the fibula is
made longitudinally extending from the fibular head and ends just proximally to
the lateral malleolus. Anterior and posterior skin flaps are created; the anterior
and lateral compartments are identified, and, using dissecting scissors,
longitudinal fasciotomies are performed. It is essential to identify and protect the
superficial peroneal nerve in the distal third of the leg piercing out of the fascia
from the lateral compartment. Using the posterior flap created and while
elevating the structures in the lateral compartment, the superficial posterior
compartment is exposed, and the fascia is incised. Subsequently, the soleus
ridge is identified, and the soleus muscle is detached from the fibula in order to
expose the deep posterior compartment and decompress it. Subperiosteal
dissection is performed around the posterior side of the fibula as well to
decompress the deep posterior compartment (Forsh & Wolinsky 2013; Gourgiotis
et al. 2007; Lawendy & Sanders 2010).
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I.1.2 Two-Incision Fasciotomy
The patient is set up the same way as in the single-incision technique. A
20-25cm longitudinal incision is performed midway between the fibula and tibial
crest (Figure I.1). Anterior and posterior skin flaps are created, and the lateral
intermuscular septum is identified. Fasciotomies of the anterior and lateral
compartments in line with the tibialis anterior and fibular shaft, respectively, are
performed. Care is taken to identify the superficial peroneal nerve piercing
through the fascia of the lateral compartment in the distal third of the leg.
Attention is then turned towards the medial aspect of the lower leg. A medially
based longitudinal incision is made 2cm posterior to the medial aspect of the
tibia. The skin is retracted posteriorly, the saphenous nerve and vein are
identified and protected, the septum dividing the superficial and posterior
compartments is identified and released, and the fascia overlying the
gastrocnemius-soleus complex is released. An incision overlying the flexor
digitorum longus is then made to access and decompress the deep posterior
compartment. When the soleus bridge is extended more than halfway down the
tibia, its extended origin is also released in order to access the deep posterior
compartment. (Forsh & Wolinsky 2013; Gourgiotis et al. 2007; Lawendy &
Sanders 2010). For both techniques, the wound is left open with packing or loose
skin closure for later primary closure or skin grafting. The leg is splinted with the
foot plantigrade (Lawendy & Sanders 2010; von Keudell et al. 2015).
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Figure I.1.

Two-incision fasciotomy. The lateral incision is centred halfway
between the fibular shaft and the crest of the tibia. Lateral
intermuscular septum is exposed. The anterior compartment is
released in line with the tibialis anterior while the lateral
compartment is released in line with fibular shaft. A medial
longitudinal incision 2cm posterior to the posterior margin of the
tibia is created; gastrocnemius-soleus complex fascia is released
followed by deep posterior compartment release via fascial incision
over the flexor digitorum longus.
Reproduced with permission from Lawendy and Sanders (2010).
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I.2 FOREARM FASCIOTOMY
I.2.1 Volar Approach
The volar incision is performed using either a radial or ulnar curvilinear
incision. Regardless of the choice of incision, the volar incision must begin
proximal to the elbow flexion crease and terminate past the wrist crease (Figure
I.2). Incisions at the elbow and wrist flexion crease are made at an oblique angle
to avoid contracture. Proximally, the lacertus fibrosis is released and the brachial
artery is explored. The mobile wad, flexor carpi ulnaris and its neurovascular
bundle, flexor digitorum superficialis, and median nerve are decompressed,
explored, and retracted. The fascia and epimysium overlying the flexor digitorum
profundus are then incised. Distally, the carpal tunnel is always released during
forearm fasciotomy. A distal volar ulnar approach to explore Guyon’s canal may
be used when the ulnar nerve is affected (Forsh & Wolinsky 2013; Lawendy &
Sanders 2010).

I.2.2 Dorsal Approach
Typically, a volar approach alone is sufficiently adequate to decompress
the forearm. Nonetheless, posterior compartment pressures must be assessed. If
needed, a dorsal incision extending from 2cm distal to the lateral epicondyle to
the centre of the wrist at the level of the radioulnar joint is made for the posterior
forearm. Subsequently, the fascia overlying the extensor retinaculum and the
mobile wad is decompressed, and the muscles of the mobile wad are individually
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Figure I.2

Fasciotomy of the forearm. A volar curvilinear incision is
performed, the superficial volar compartment is then released by
identifying the mobile wad, flexor digitorum superficialis, flexor carpi
ulnaris, and median nerve. Then, the flexor digitorum profundus in
the deep compartment is exposed by incising the fascia
longitudinally. Proximally, the lacertus fibrosis is released while
distally, the carpal tunnel is decompressed.
Reproduced with permission from Lawendy and Sanders (2010).
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released. The incision(s) are kept open with moist gauze for later primary closure
or skin grafting, and the arm is splinted with the elbow below 90 degrees of
flexion (Forsh & Wolinsky 2013; Lawendy & Sanders 2010).
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